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Introduction and outline
The endothelial glycocalyx
The endothelial glycocalyx or endothelial surface layer (EG), is a negatively charged gel-
like surface structure of proteoglycans with their covalently bound polysaccharide chains 
called glycosaminoglycans (GAGs), glycoproteins and glycolipids. Its main carbohydrate 
constituents are heparan sulfate (HS), chondroitin sulfate (CS) and hyaluronan (HA). The 
endothelial glycocalyx governs transcapillary fluid exchange and acts as biomechanical 
sensor to confer shear to the endothelium (EC) [1-3]. Glycosaminoglycans within the 
glycocalyx function as a molecular scaffold that facilitates protein binding in a very 
selective manner. In this way, circulating proteins, such as growth factors and chemokines 
are concentrated and spatially organized in gradients at the endothelial surface [4,5]. 
The proteins that bind to the glycocalyx include proteins involved in cell attachment, 
migration, differentiation, morphogenesis, blood coagulation, lipid metabolism, 
and inflammation, thus putting the endothelial surface layer at the very center of the 
pathophysiology of cardiovascular and renal disease (figure 1). However, despite its 
pivotal role in endothelial cell biology, glycocalyx function has proven to be hard to 
study due to its complex carbohydrate chemistry and the difficulties in interrogating its 
function in vivo and in vitro. Here we will describe the structure and main biological 
functions of the endothelial glycocalyx in the kidney and an give an outline of this thesis.
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Figure 1: Schematic overview of the endothelial glycocalyx in a healthy and diseased condition. 
Left: In a physiological state, the endothelial glycocalyx protects against protein leakage, 
inflammation and coagulation. Heparan sulfates, bound to a heparan sulfate core protein, and 
hyaluronan, bound to e.g. CD44, are the main constituents of the endothelial glycocalyx (EG). Order 
and modification of disaccharide repeats within HS determine the binding site for specific proteins. 
Right: Upon endothelial activation, heparan sulfate disaccharide modification occurs, resulting in 
a change in protein binding sites. During a chronic disease condition, the EG gets damaged, mainly 
due to up regulation of degrading enzymes such as hyaluronidase, heparanase and proteinases. 
Both HS modification and EG degradation result in inflammation, coagulation and protein leakage.
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Biochemical structure of the endothelial glycocalyx
The membrane bound part of the endothelial glycocalyx consists of proteoglycans, 
glycosaminoglycans, glycoproteins and glycolipids. Proteoglycans with their bound 
GAGs are the main contributors to the EG structure and function[6]. Of these GAGs, 
heparan sulfate and hyaluronan constitute up to 90% [7-9].
Heparan sulfate is a linear polysaccharide which consists of the repeating disaccharide β1–
4-linked D-glucuronic acid (GlcA) and α1–4-linked N-acetyl-D-glucosamine (GlcNAc). 
This polymer is covalently attached to a limited number of core proteins at cell surface, 
called heparan sulfate proteoglycans (HSPGs). The proteoglycans found on the luminal 
endothelial side are syndecans 1 and 4, glypican 1, versican and thrombomodulin. HS 
chains are processed in the Golgi apparatus were they undergo a series of modifications 
in which subsets of glucosamine residues can become N-deacetylated and N-sulfated 
and where glucuronic acids may undergo epimerization to L-iduronic acid (IdoA). 
In particular, C2 of uronic acid and C6 (and rarely C3) of  glucosamine residues may 
become sulfated [10]. After intracellular processing, further extracellular modification 
can occur. Heparanase (HPSE1) and endosulfatases (SULF1,2) can cleave the HS chain 
or further modify the sulfate groups within HS, respectively [11]. (figure 2) Although 
they do attribute to a wide variety of specific HS binding sites for protein interactions 
that determine endothelial cell biology, regulation of these modifications is still not well 
understood. While the core proteins can function independently of the HS chains they 
carry, the HS chains predominantly dictate ligand-binding capability and therefore 
the biological roles of HSPG. Some examples are discussed in the next section.  HS is 
structurally related to heparin, a highly sulfated GAG [10-12].
Hyaluronan lacks the complex chemical editing of HS. It is a nonsulfated 
glycosaminoglycan composed of repeating polymeric disaccharides D-glucuronic acid 
and N-acetyl-D-glucosamine linked by a glucuronidic bond [2,3]. Under physiologic 
conditions, hyaluronan is synthesized by membrane bound synthases (HAS1, 2 and 3) 
as a macromolecule of 105–107 Da. Following its synthesis, hyaluronan is directed to the 
cell surface where it interacts with hyaluronan binding surface proteins (hyaladherins) 
such as CD44, or is assembled into the pericellular extracellular matrix [1]. The repeating 
nature of the polysaccharide and hence its protein binding sites, has been suggested to 
confer structural periodicity to the endothelial surface layer [13]. The main modifiers 
of hyaluronan are hyaluronidases, enzymes that cleave high molecular weight (HMW) 
hyaluronan chains into smaller low molecular weight hyaluronan fragments.
1
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Figure 2
Figure 2: Schematic overview of production and modification of HA and HS. Top left: Hyaluronan 
(HA) is produced by HAS2 and transported over the cell membrane by ABC transporters, where it 
can bind to several HA binding proteins. Bottom left to upper right: Heparan sulfate (HS) containing 
proteoglycans are produced in the endoplasmic reticulum and Golgi apparatus. HS initiation 
starts with the addition of linker pentasaccharides to serine residues within the backbone protein 
(1). Two enzymes, exostosin1 and 2 (EXT1/EXT2) form the initial heparan sulfate chain by adding 
alternating  N-acetyl-glucosamine (GlcNAc) and glucuronic acid (GlcA) (2). 4 different isoenzymes 
of N-deacetylation/N-sulfation (NDST) enzymes modify the chain by removing N-acetyl groups from 
subsets of GlcNAc subunits and substituting this free group with sulfate.(3) Glucuronic acid (GlcA) 
can be epimerized into iduronic acid (IdoA) by glucuronic acid epimerase (GLCE) (4) Isoforms of 
sulfotransferases transfer sulfate to 2-O, 3-O or 6-O residues (5). The HS proteoglycan is transported 
towards the endothelial membrane where it can be modified by the extracellular enzymes heparanase 
and sulfatase (6). Together all these enzymes are responsible for the structure and thus the ability to 
bind proteins such as fibroblast growth factor (FGF).
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Function of the endothelial glycocalyx
Biomechanical properties 
The endothelial glycocalyx is believed to be the primary molecular sieve for plasma proteins 
and, therefore, the origin of the oncotic forces that control transcapillary fluid exchange. 
This has led to a revised Starling principle in which the capillary filtration equilibrium is 
generated over the glycocalyx, rather than across the entire endothelial layer as had been 
widely assumed [14]. Within the glycocalyx, hyaluronan is a key determinant of many 
biomechanical and hydrodynamic properties such as its function in fluid exchange 
and shear sensing properties [15-19]. In particular, its physical properties in solution 
contribute to the function of hyaluronan [2,20,21]. Even small amounts of hyaluronan 
can bind large amounts of water molecules, forming a gel-like structure. Small molecules 
like water, electrolytes and nutrients can freely diffuse through the solvent. In contrast, 
large molecules, such as proteins, are excluded because of their hydrodynamic sizes in 
solution. In this way, hyaluronan contributes to the barrier function of the endothelial 
glycocalyx. The negative charge of the sulfated heparan groups in HS chains further 
adds to the barrier function of the glycocalyx, by repelling negatively charged circulating 
proteins like albumin. 
An intact glycocalyx also serves as the primary sensor of shear stress on ECs. 
Hydrodynamic drag arising from flowing plasma through this layer transmits fluid shear 
stress through the thin sub-layer where proteoglycans, glycoproteins and glycolipids are 
directly linked to the endothelial cytoskeleton [22]. Both, the presence of hyaluronan, 
possibly by linking to the epithelial sodium channel (ENaC) in the endothelium, and HS 
appear to be critical for this function [23]. For example, enzymatic removal of hyaluronan 
or HS from the glycocalyx results in reduced nitric oxide (NO) release during shear [17]. 
Heparinase III, a bacterial enzyme that cleaves HS proteoglycans, has a dramatic effect 
on the ECs’ ability to produce NO to shear stress and transfer shear forces to the actin 
cytoskeleton [8,24]. Interestingly, the enzyme chondroitinase, employed to selectively 
degrade CS, did not affect shear-induced NO production, underpinning the importance 
of HS for the biomechanical properties of the endothelial glycocalyx [25].
Inflammation
The gel-like anti-adhesive properties of the endothelial glycocalyx preclude direct 
leukocyte interaction with adhesion molecules on the endothelial surface. However, 
during their passage through the capillaries the leukocytes will compress the endothelial 
glycocalyx thus allowing for engagement of the microvilli of the leukocyte with the 
GAGs in the glycocalyx. For example, HS on the endothelium acts as a direct ligand for 
L-selectin [26,27]. Interestingly, this interaction is modulated by very specific HS sulfation 
patterning. Endothelial deletion of the biosynthetic enzyme, N-acetylglucosamine 
N-deacetylase-N-sulfotransferase-1 (NDST1) which leads to decreased sulfation of the 
HS chains in the endothelium, reduces the binding of L-selectin, and leads to an increase 
in neutrophil rolling velocity [28]. Inflammatory stimuli, such as TNF-α, induce 
1
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NDST1 which results in expression of HS domains on glomerular endothelium that are 
associated with inflammation [29,30]. In agreement, we recently showed that endothelial 
deletion of NDST1 results in reduced leukocyte extravasation in experimental anti-GBM 
glomerulonephritis [30].
The migration of leukocytes across the endothelium occurs along chemoattractant 
gradients composed of chemokines that have bound to the endothelium [5]. Nearly all 
members of the chemokine family bind to HS by way of a positively charged C-terminal 
domain. Again, this binding may be modified by chemical editing of HS chains. For 
example, changing the domain structure of HS by inactivation of HS2ST (which causes 
a compensatory increase in glucosamine N-sulfation and 6-O-sulfation) results in 
enhanced binding of IL-8 to the endothelium and increases inflammation [31]. 
Endothelial HS has also been shown to be critical for the function of the complement 
system. The function of many of the components of the complement system, including C1, 
C1q, C1 inhibitor, C2, C4, C4b, FactorB, FactorD, FactorH, Properdin, and complement 
receptors CR3(CD11b/CD18) (24) and CR4 (CD11c/CD18) is dependent upon binding to 
specific glycosaminoglycan domains [32-34]. The clinical importance and the specificity 
of these interactions are illustrated by patients with mutations in the short consensus 
repeats 19 and 20 of  the complement inhibitor, factor H. These mutations result in 
impaired binding of factor H to the glomerular endothelium, but not to other endothelial 
beds. Upon a trigger that activates the complement system this may result in glomerular 
endothelial injury and  presents itself clinically as atypical hemolytic uremic syndrome 
[35].
In addition to HS, hyaluronan has also been demonstrated to modulate inflammatory 
processes. The HMW form of hyaluronan possesses anti-inflammatory, anti-angiogenic, 
and immunosuppressive properties and protects cells from injury, and leukocyte 
adhesion [36]. In part this is related to its gel-like physical properties.  In addition, 
binding of tumor necrosis factor (TNF)-stimulated gene 6 (TSG-6) to hyaluronan 
inhibits chemokine-stimulated trans-endothelial migration of neutrophils via a direct 
interaction between TSG-6 and the glycosaminoglycan-binding site of CXCL8 [37]. 
However, during tissue injury and inflammatory processes hyaluronan can become 
depolymerized through oxidative stress and enzymatic cleavage by hyaluronidases. This 
results in the formation of low molecular weight (LMW) hyaluronan fragments [38]. 
Removal of LMW hyaluronan from sites of injury is dependent on their interaction with 
CD44, and the associated downstream signaling events have been implicated in cell 
proliferation, migration and activation. LMW hyaluronan also has been demonstrated 
to interact with Toll-like receptors enabling hyaluronan signaling in inflammatory cells 
[38,39]. 
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Anticoagulation 
Both the biomechanical properties as well as glycocalyx-protein interactions play a 
prominent role in preventing the blood from clotting. The gel-like properties of the 
glycocalyx prevent platelets from accessing the endothelium [40]. HS in the glycocalyx 
is required to activate antithrombin, a serine protease that inhibits thrombin and 
thus the conversion of fibrinogen to fibrin. By acting as a scaffold and simultaneously 
binding to both enzyme and substrate, HS greatly increases engagement of thrombin 
with antithrombin [41,42]. This interaction depends upon a specific pentasaccharide, 
an insight that led to the clinical development of fondaparinux. By binding the plasma 
protein Heparin cofactor II (HCII), heparan sulfate repeats in the glycocalyx further 
inhibit the pro-coagulant activity of thrombin. The latter pathway has been shown to 
counteract thrombus formation in the presence of endothelial injury [43].
A key regulator of the natural anticoagulant system is the endothelial glycocalyx protein 
thrombomodulin. Upon binding of thrombin it generates activated protein C (APC). APC 
regulates blood coagulation by cleaving and inhibiting two cofactors, activated factor 
V (FVa) and activated factor VIII (FVIIIa), which serve as phospholipid- membrane-
bound cofactors to factor Xa (FXa) and factor IXa (FIXa), respectively. APC not only has 
anticoagulant properties, but also through PAR signaling induces a quiescent phenotype 
in the endothelium [44,45]. Activation of this pathway could prevent the development 
of diabetic nephropathy, underscoring the importance of APC formation in prevention 
of kidney disease [45]. Finally, thrombomodulin-thrombin binding activates thrombin-
activatable fibrinolysis inhibitor (TAFI) thus suppressing fibrinolysis at the same time. 
This system is intensively modulated by interactions with glycosaminoglycans. First, 
thrombomodulin can bind chondroitin sulfate, greatly facilitating the interaction with 
thrombin and the formation of APC [46,47]. The activity of APC and thrombin in their 
turn are negatively regulated by protein C inhibitor which form together with different HS 
repeats ternary complexes [48]. While very complex and still only partially understood 
the intricate interaction of the coagulation system with the glycocalyx demonstrates the 
importance of the latter as a molecular scaffold.
1
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Risk factors for endothelial glycocalyx degradation
The EG has a vulnerable location between the endothelium and flowing blood which 
might contain circulating risk factors such as glucose, lipids and inflammatory 
intermediates. In patients, acute hyperglycemia is associated with perturbation of EG 
and vascular permeability [49]. In diabetes mellitus type 1 (DM1) patients, increased 
levels of circulating hyaluronidase were observed [50]. In vitro, both an upregulation of 
the EG degrading enzyme heparanase [51] and a marked reduction in the biosynthesis of 
GAGs was observed upon high glucose stimuli in glomerular endothelial cells (GEnCs) 
[52].  An association between plasma LDL cholesterol levels, reduced expression of 
endothelial GAGs and increased wall thickness at carotid lesion-prone sites was observed 
in previous studies, suggesting glycocalyx damage during hyperlipidemia [53,54]. These 
data concur with a study that demonstrates partial restoration of endothelial glycocalyx 
volume upon normalization of LDL levels [55]. Another type of risk factors affecting 
the endothelial glycocalyx are inflammatory mediators. For example, TNFα increases 
permeation of macromolecules into the ESL in hamsters and also LPS administration 
results in an induced dysfunction of the microcirculation accompanied by glycocalyx 
degradation [56]. Also, TNFα stimulation has been demonstrated to change expression 
of HS modifying enzymes and increase inflammatory epitopes within GEnC HS [29].
Endothelial damage upon stimulation with risk factors can occur both directly, such 
as by oxygen radicals produced during cellular stress that alter the composition of 
the EG [57-59], as well as indirectly through chronic stimulation resulting in changes 
in production and modification of GAGs by changing the expression of the involved 
synthesizing- and or degrading enzymes such as hyaluronidase and heparanase [50,58]. 
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Current treatment options to stabilize the endothelial glycocalyx
The proposed role of the EG as target for cardiovascular risk factors implies that the 
EG could be an interesting target for therapies against the development of vasculature-
born pathologies. First of all, as endothelial dysfunction seems to be closely associated 
with endothelial glycocalyx loss, current medication based on improving vascular or 
endothelial function will most likely also affect the endothelial glycocalyx. Stabilizing 
the endothelium, for example with angiopoietin 1 (Ang1), has been shown to enhance 
glycocalyx thickness in frog mesenteric cells and increase GAG production in human 
microvascular endothelium [60].
In contrast to these indirect effects, several options have been proposed to directly 
influence endothelial glycocalyx. This is done by GAG supplementation. One of the most 
well studied glycosaminoglycan supplements is sulodexide; a highly purified mixture of 
low molecular weight heparin (80%) and dermatan sulfate (20%). Although its function 
has been prescribed to different mechanisms over the past years, its anti-albuminuric 
effect has been demonstrated in several studies [61-63]. For example, in male participants 
with type 2 diabetes (T2D), sulodexide administration led to an increase in systemic 
glycocalyx thickness. It showed a reduction in plasma hyaluronidase, as well as a trend 
towards the normalization of systemic albumin clearance [64]. Although a recent study 
showed that sulodexide failed to demonstrate renoprotection in overt type 2 diabetic 
nephropathy patients [65], this can most likely be explained by the progression of type 
2 diabetes. Restoring the EG has the most significant effects during the early stages 
of the disease, before irreversible morphological changes within the kidney occur. 
Indeed, animal studies showed that sulodexide ameliorates only early disease in models 
of radiation nephropathy and diabetic nephropathy in rats [66]. Nonetheless, the 
disadvantage of sulodexide is the heterogeneity of the composition, which might also 
explain the diversity in study results.
To solve this heterogeneity problem, a purified glycosaminoglycan should be produced. 
This targeting of specific heparan sulfate modification patterns seems to be a promising 
upcoming field. Several oligosaccharides and single chain antibodies directed against 
specific oligosaccharide compositions are being screened for their potential to block the 
HS moieties that initiate inflammation and angiogenesis on the endothelial surface [67-
70]. The other way around, small peptides that resemble the HS binding region within 
a specific protein, might be developed to block the HS binding site. Furthermore, since 
increased amounts of heparanase and hyaluronidase are associated with a high variety of 
diseases, inhibiting such glycocalyx degrading enzymes might be interesting for future 
studies [71]. 
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The endothelial glycocalyx in the glomerular filtration barrier
The kidney
In addition to the general composition and function of the endothelial glycocalyx in 
the vasculature, we studied the role of the endothelial glycocalyx in renal filtration. The 
human kidney contains approximately 0.8-1.5*10^6 nephrons, which are the functional 
units of the kidney. The normal glomerular filtration rate ranges from 130-180 liters 
per day [72]. Circulating blood enters the glomerulus via the afferent arterioles. In the 
glomerulus ultrafiltration takes place (figure 3). Here, water and small solutes, like salts, 
can pass through the glomerular filtration barrier, while larger molecular like proteins 
and cells are retained within the circulation. 
Figure 3: Structure and function of the kidney and glomerulus. One of the main functions of the 
kidney is glomerular filtration. Blood enters the kidney (top left) and flows through the afferent artery 
into the glomerulus (bottom left). Here the blood is filtered: fluid containing small solutes passes the 
filtration barrier, while bigger components, such as proteins are maintained within the vasculature. 
The glomerular stalk (right) consists of mesangial cells, endothelial cells, glomerular basement 
membrane and podocytes. The combination of these cells is necessary to maintain the structure 
and function of the glomerulus. The filtration barrier, better shown in figure 4, is responsible for 
the filtration within the glomerulus. The bowman’s space, where the filtrate is collected, is lined 
by parietal epithelial cells. From here, the filtrate goes through the tubuli, where reabsorption of 
essential components such as glucose and sodium takes place.
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Barrier function in the glomerulus
Although still under some debate [73], most evidence points towards the glomerular 
filtration barrier (GFB) as the main site of filtration. Farquhar demonstrated, using 
electron microscopy, that in intact glomeruli only about 0.06% of plasma albumin gets 
filtrated [74,75].  Although tubular reabsorption may play a role in fine-tuning the leakage 
of albumin, the GFB is assumed to play the key role in filtration. This filtration function 
of the GFB is maintained by the three layers of the filtration barrier: endothelium, 
glomerular basement membrane (GBM) and podocytes. Together with the mesangium, 
these components form the glomerulus: a unique non-clogging filter that can endure 
the filtration for over a lifetime. Although all layers and its specific roles within the GFB 
are often studied separately, it should always be taken into account that all these layers 
depend on each other’s structure and function to form this highly specialized glomerular 
filtration barrier. For example, disturbed VEGF signaling from the podocytes affects 
endothelial health [76], and perturbed PDGF signaling from the endothelium affects the 
mesangium [77].
Until recently, it was reasoned that the endothelial layer could not contribute to the 
filtration barrier because of its large fenestrae. These fenestrae lack a diaphragm and 
can therefore be considered as holes of about 60-80 nanometer [78]. These holes support 
the passage of high volumes of water, but are also large enough to allow proteins like 
albumin to pass the endothelial layer. Consequently, most studies focused on the GBM 
and podocytes as main components of the filtration barrier. However, recently Weil et al. 
showed that changes in the endothelial layer were associated with glomerular filtration 
rate and albumin-creatinine ratio in T2D patients [79,80]. 
A role for the endothelium in the filtration barrier is further supported by the little 
variation in reflection coefficient between fenestrated and continuous capillary beds 
[81,82]. Ryan et al. demonstrated that under physiological conditions hardly any 
albumin is observed in the GBM or underlying podocytes [83]. This can be explained by 
the observation that endothelial fenestrae are filled with endothelial glycocalyx [84,85]. 
Consequently, the endothelial glycocalyx within the fenestrae was proposed to be the 
first barrier within the GFB that excludes proteins [86]. Glycosaminoglycan-degrading 
enzymes such as chondroitinase and heparinase have been shown to alter the charge 
selectivity of the glomerular filter [87,88]. In addition, even local displacement of only 
the non-covalently bound components of the renal glycocalyx has been demonstrated 
to result in a 12-fold increase in fractional albumin clearance [89]. This indicates that 
besides GAGs, the loosely bound plasma proteins are also essential for the structure of 
the endothelial glycocalyx and for the barrier function of the glomerulus. 
Although these data clearly indicate a role for the endothelial glycocalyx as filtration 
barrier, the exact mechanism is yet unknown. It has been postulated that glycocalyx 
polyanions such as heparan sulfate and sialated proteins on the surface of the endothelium 
and podocytes, as well as in the glomerular basement membrane would electrically repel 
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the negatively charged albumin [90,91]. Although this is supported by data with non-
metabolizable negatively charged probes that would support that electric charge would 
modify filtration of albumin [92,93], this concept has been challenged by in vivo studies 
of the fractional clearance of negatively charged Ficoll as compared with Ficoll where 
negative charge selectivity did not exist [94,95]. 
Irrespective of the debate about charge exclusion, it is very plausible that the glycocalyx 
acts as a size barrier to albumin filtration. The glycocalyx basically functions as a 
hydrogel where glycosaminoglycans, i.e. heparan-, chondroitin sulfate and hyaluronan, 
constitute a fiber mesh with pores [20,96,97]. Plasma proteins bind multivalent to these 
glycosaminoglycans, thus creating steric hindrance to protein filtration. This barrier 
function will be further modified by the fluid drag through the glycocalyx which allows 
for  dynamic equilibrium with glycocalyx-bound and free circulating proteins [98]. 
Such a size barrier function of the endothelial glycocalyx has in fact also been suggested 
from observations in the microcirculation in general, where the hydrostatic and osmotic 
forces that determine fluid filtration were shown to exist only across the glycocalyx 
and not across the endothelial cell towards the interstitium [99]. It is of interest that 
elongated molecules, such as bikunin and hyaluronan have >100-fold higher glomerular 
sieving coefficients than albumin, despite similar molecular weights and charges [100]. 
While such experiments may be challenged by confounding factors due to metabolism of 
albumin by the proximal tubulus [101], they can also be interpreted to demonstrate the 
importance of pore characteristics in relationship to the molecular conformation of the 
protein sieved. The latter is further supported by recent observations that large straight 
nanotubes (200-300 nm) may be filtered by the glomerulus similarly to small molecules 
[102]. 
20    21
Introduction and outline
Scope of this thesis
In the introduction we described a role for the EG in the onset of development in several 
vasculature-related pathologies like cardiovascular a disease, diabetes, but also renal 
failure. In this thesis the structure and function of the EG and its components in the 
vasculature in general and in the glomerular capillaries have been studied. In addition, 
methods to determine changes in the EG and the relation with known vascular damage 
markers in healthy and diseased subjects have been newly developed.
In Chapter 2, we mainly focus on the challenges in visualization and quantification 
of the endothelial glycocalyx. Here, the different methods to study ESL thickness and 
composition, both in vitro and in vivo, are discussed.
Because it has been demonstrated that EG is absent in vitro, we hypothesized that 
mimicking the in vivo situation by subjecting the cells to prolonged shear stress would 
change the endothelial glycocalyx dimensions and composition. This will be further 
discussed in chapter 3.
The EG contributes to the permeability function of the endothelium throughout the 
whole vasculature. In the fenestrated endothelium of the kidney, the EG is also present 
within the fenestrae, suggesting a role for the EG in glomerular filtration. The main EG 
component that contributes to endothelial permeability has been proposed to be HA. 
In chapter 4 we studied the role of the EG, and specifically HA, in the filtration barrier. 
Therefore, we systemically removed HA with hyaluronidase and examined the effects on 
the function of the filtration barrier.
In chapter 5, we used a novel method to measure changes in the EG in end stage renal 
disease patients. Using SDF imaging of the sublingual microvasculature, we looked 
into variations in the width of the RBC column as a measure for changes in the EG. In 
addition, we looked into endothelial activation and glycocalyx shedding to determine the 
association between renal function, endothelial dysfunction and glycocalyx shedding. 
Finally we studied the ability of the EG to recover after successful kidney transplantation.
In chapter 6 we studied the EG in a cohort of healthy but obese participants. Here 
we demonstrated the relation between microvascular perfusion and EG thickness. 
Furthermore, these participants have a higher risk for the development of cardiovascular 
disease. Therefore this study functions as baseline measurement for future follow-up 
studies. Consequently the question whether early changes in EG predict cardiovascular 
events will be studied. 
Finally, in chapter 7 this thesis is summarized and the relevance of these results in 
combination with the current knowledge in literature is discussed. Furthermore, some 
future perspectives are proposed.
1
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Introduction
Endothelial cells perform key homeostatic functions such as regulating blood flow and 
permeability, preventing leukocyte activation, and aiding immune surveillance for 
pathogens. Endothelial activation therefore has been identified as an important effector 
mechanism in progression of renal disease as well as the associated development of 
cardiovascular disease. The primary interface between blood and the endothelium is the 
glycocalyx. This carbohydrate-rich gel-like structure mediates most of the regulatory 
functions of the endothelium. Because the endothelial glycocalyx is a highly dynamic 
and fragile structure ex-vivo, studying its dimensions and function has been proven to be 
a challenge. Tissue processing for staining and perfusion-fixation, usually will result in a 
partial or complete loss of the glycocalyx. Consequently, its functions and its potential as 
a therapeutic target have often been underappreciated. Here we will outline the different 
techniques to visualize structure function relationships in kidney and vasculature. 
 
Imaging the endothelial glycocalyx
Endothelial activation has been shown to be a central mediator in the development 
of cardiovascular and kidney disease [1,2]. Because the endothelial glycocalyx is the 
primary interface for interaction of blood with the vessel wall, it can be postulated that 
endothelial activation in fact is primarily mediated through changes in EG function or 
composition. Well known risk factors for the development for cardiovascular and renal 
disease such as diabetes have been associated with both upregulation of heparanase and 
hyaluronidase [3,4], resulting in degradation or loss of glycocalyx. For example, increased 
activity of heparanase has been demonstrated in both circulating mononuclear cells as 
well as the plasma of hemodialysis patients and linked to the presence of atherosclerotic 
lesions [5]. Because the EG is a highly dynamic and fragile structure, it is unstable when 
taken out of its in vivo environment. Consequently, bound plasma components and 
GAGs can be lost during fixation, dehydration, sectioning and staining procedures. As a 
result, only membrane bound parts of the glycocalyx will remain. Avoiding this loss of 
the EG is one of the biggest challenges in EG visualization. Attempts to visualize changes 
in EG composition and thickness, have led to imaging techniques based on different 
characteristics of the EG. 
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Figure 1:  Three methods to stabilize and stain the endothelial glycocalyx for electron microscopy. 
A) Alcian Blue 8X stained artery (left) and detailed image of an Alcian Blue 8x stained myocardial 
capillary.  B) Cupromeronic Blue stained vein (left) and detailed image of glomerular capillary 
(right).  C) Cationic Ferritin stained vein (left) and detailed image of glomerular capillary (right). 
Scale bars represent 500 nm (left) and 200 nm (right)
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Electron microscopy
Preserving and staining the EG for EM
The high polysaccharide content of the EG interacts poorly with the commonly used 
post-fixation stains. As a result, the EG scatters few electrons and is indistinguishable 
from its environment in conventionally processed  samples for TEM [6]. Thus, even if 
the pre-treatment of the sample maintains the structural integrity of the endothelial 
glycocalyx, an additional staining or preservation is required for visualization of the EG 
in TEM. This explains the absence of visible EG structures in almost all tissues that are 
conventionally processed for TEM. The first to succeed in staining the EG for electron 
microscopy was Luft in 1966, who used ruthenium red, or ammoniated ruthenium 
oxychloride, which stains the aldehyde fixed mucopolysaccharides in the EG and 
generates an electron dense stain in the presence of osmium tetroxide [7]. 
The presence of the luminal EG has subsequently been shown using TEM in combination 
with a variety of staining and preservation techniques such as ruthenium red, ferritin, 
and lanthanum. Most of these agents cationic dyes bind to the negative charge of the 
sulfated GAGs and form an electron dense contrast together with osmium tetroxide, to 
enable visualization [8-12]. Using alcian blue 8GX, van den Berg et al. were the first to 
be able to better stabilize the anionic carbohydrate structures in myocardial capillaries, 
thereby visualizing an impressive EG of up to 500 nm thick [13]. The saccharine nature of 
these visualized structures was confirmed by perfusion of gold-labelled lectins before the 
staining procedure. Recently, we were able to visualize the EG in the renal glomerulus 
using cupromeronic blue, a chemically more stable cationic dye resembling some alcian 
blue properties [14]. This revealed a staining of matrix polysaccharides on the luminal 
surface of the glomerular endothelial membranes and a dense staining of polysaccharide 
matrix within the fenestrae. Examples of the described staining procedures are shown 
in figure 1.
High pressure freezing 
Because optimal preservation of the EG and its visualization requires the use of perfusion 
fixation techniques, it has not been possible to reliably image the EG in patient biopsy 
material. Although not yet used for this purpose, a combination of rapid freezing and 
freeze substitution of the tissue might be an interesting way to preserve the EG. With a 
combination of instantaneous high pressure and a rapid decrease in temperature, high-
pressure freezing preserves the tissue while reducing the formation of ice crystals. In a 
frozen state water can be replaced and tissue can be stained at the same time. This way 
molecules can be fixated in plastic, while preserving their native structure as much as 
possible. Results of this procedure are shown in the example of a high pressure frozen 
mouse renal sample which is stained during freeze substitution with acridine orange 
and uranyl (figure 2). Although further optimization is necessary, it does appear to be 
a promising technique that might pave the way for studying changes in the local EG in 
patients.
2
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3-Dimensional EM imaging
Over the recent years some interesting developments took the field of electron microscopy 
to a next level. These new methods might be used to better and more reliably study the 
EG. In regular EM imaging techniques, the highly detailed 2-dimensional EM images 
are prone to selection bias, as only a small area of interest is shown. To avoid this operator 
introduced selection bias, Faas et al. developed a method which provides high resolution 
and high detailed images while maintaining the lower resolution overview of the cellular 
context [15]. Examples of images in which virtual zooming was used on a stitch of a 
Cupromeronic blue stained glomerulus are shown in figure 3. 
Interestingly, within one stitch of a mouse glomerulus different structural organizations 
of the EG can be observed, depending on its location (figure 3B non-fenestrated (top) vs 
fenestrated (bottom) endothelium). In addition 3D imaging can also be used to decrease 
bias and obtain more insight in the imaged structures. Based on earlier publications where 
bacterial flagellae were imaged [16], Arkill et al. succeeded to make a 3D reconstruction 
of the EG using 3D electron tomography.  In electron tomography, an electron beam 
passes through the sample which is tilted after every image so that images can be taken 
at different angles. By reconstructing these images, a 3D image of the sample can be 
produced [17]. Although not used for EG imaging yet, some newer techniques, like SEM 
with a built-in microtome and focused ion beam scanning electron microscopy (FIB-






Figure 2: EG in a glomerular capillary of a high pressure frozen kidney section. EG was stained 
with acridin orange and uranyl during the freeze substitution stage. Overview (left) and detailed 
image of the glycocalyx on top of the glomerular filtration barrier (right). EC: endothelial cell, GBM: 
glomerular basemenent membrane, P: Podocytes, Glx: Glycocalyx. Scale bars represent 500 nm (left) 
and 200 nm (right).
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A
B
Figure 3: Transmission electron microscopic images of a cupromeronic blue stained glomerulus. 
A) Overview (left) and virtual zoom (right) of a stitch of a mouse glomerulus. B) Virtual zoom 
with maximal detail showing different structures of the endothelial glycocalyx on top of continuous 
endothelium (left) and fenestrated endothelium (right). Scale bars represent 10 µm (left) and 1 µm 
(right) (A) and 100 nm (B).
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Fluorescence microscopy
Staining and imaging specific EG components
The carbohydrates within the EG have been imaged using specific lectins, mostly in 
combination with fluorescence microscopy. Lectins are carbohydrate binding proteins 
that recognize specific sugar moieties and 3D configurations. One of the most commonly 
used lectins is wheat germ agglutinin (WGA). Although lectin staining of the EG can be 
used to study changes in dimensions, they do not allow  to determine changes in the 
specific composition of different GAGs. Consequently, antibodies are needed to more 
specifically determine compositional changes within the EG. 
Over the recent years several antibodies have been obtained against specific carbohydrate 
domains within heparan sulfates (e.g. JM403, 10E4 and HEPSS1), hyaluronan and 
chondroitin sulfates or against the proteoglycan core proteins such as syndecan, 
glypican or perlecan [19-24]. Chondroitin sulfate and hyaluronan have been shown 
to be present on the endothelium, using an anti-CS antibody and by capitalizing on 
the protein binding properties of HA with a fluorescent hyaluronan binding protein 
(HABP), respectively [24-26]. Although all these techniques have shown the presence 
of glycocalyx components on the endothelial cells, a considerable part of these studies 
have been performed using epi-fluorescence microscopy, which has major limitations 
with respect to optical spatial resolution necessary for imaging the luminal endothelial 
glycocalyx. 
With the development of confocal and two photon laser scanning microscopy (TPLSM), 
fluorescence microscopy has been improved in such a way that the resolution is high 
enough to be used for detailed EG imaging in situ. Examples of in situ stained mouse 
glomerulus and WGA perfused isolated carotid arteries, imaged with multiphoton 
microscopy are shown in figure 4. The so-called super-resolution microscopy, such as 
stimulation emission depletion (STED), ground state depletion (GSD) and saturated 
structured illumination microscopy (SSIM) even enables higher detailed imaging than 
the conventional confocal microscopy. 
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Figure 4: Endothelial glycocalyx imaged ex vivo with confocal- or multiphoton imaging tech-
niques. A) Mouse glomerulus visualised with anti-CD31 antibodies and TRITC-labeled conjugate 
for endothelium (red), syto41 for nuclei (blue) and lycopersicon esculentum (LEA) for EG (green).B) 
Mouse glomerulus visualised with LEA (green) and wheat-germ agglutinin WGA (Red). C-D) 
Mouse common carotid artery images obtained with two-photon laser scanning microscopy show-
ing part of the vessel wall. Vessel was perfused with FITC-labeled WGA (green) and SYTO 41 (blue). 
Endothelial glycocalyx is almost inaccessible to WGA in normal situations (C, upper part) and 
becomes visible after exposure to a small air bubble (C, lower part). 3D reconstruction shows that 
the endothelial glycocalyx stained by WGA covers the endothelium (D) Bar represents 50 µm. The 
arrows indicate the direction of the X, Y, and Z axis. 
2
36    37
New labels for imaging the EG: Single chain antibodies
A complex but promising field for studying heparan sulfates within the EG is the use of 
single chain antibodies. For the selection of these single chain antibodies, a synthetic 
single-chain variable fragment library is used. Out of these single chain variable 
fragments, specific antibodies can be selected. In this way, antibodies against tissue 
specific modified HS domains can be produced. This method has been used previously 
to study heparan sulfate domains present in the basement membrane [27].  Although 
the same principle is used to study the role of heparan sulfates present on glomerular 
endothelial cells [28], it has never been used to image these heparan sulfates specifically 
on the luminal endothelial surface. Therefore, the use of single chain antibodies in 
conditions that allow for EG staining might be interesting to obtain more insight in 
the complexity of the different subcomponents within the EG. This promises to be an 
interesting field for the development of new antibodies specific for certain GAG domains 
within the luminal EG.
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Measuring and imaging structural characteristics
Circulating markers of the glycocalyx
In response to reactive oxygen species (ROS) or other inflammatory mediators, both 
single GAGs and proteoglycans can be shed from the endothelium [29-31]. This has been 
suggested to be mediated by endoglycosidases such as heparanase and hyaluronidase, 
or proteases such as matrix metalloproteases [30,32,33]. Consequently, measuring shed 
glycocalyx components might be used as a marker for endothelial glycocalyx stability. 
For example, syndecan-1 and heparan sulfate are released from the tissue and can be 
detected in the circulating blood of patients with perioperative global or regional ischemia 
[34,35]. The glycocalyx core protein syndecan-1 acts as negative regulator of endothelial 
activation [36] and has been shown to be critical for processing and inactivation of 
heparanase on the cell surface [37].  In addition, release of the endothelium specific 
proteoglycan thrombomodulin has been shown to coincide with diabetes and diabetic 
nephropathy [38,39]. We demonstrated that patients with renal failure have increased 
circulating levels of syndecan-1 and thrombomodulin, which was reversed by kidney 
transplantation [40]. Furthermore, renal failure was shown to correlate with increased 
concentrations of shed HA [41]. Altogether, while several glycocalyx components are 
shedded upon endothelial activation,  the exact location, mechanism and timing of 
shedding is complex and mostly unknown. Interpreting the results is still challenging.
Atomic Force microscopy
To determine the elastic properties of the EG, atomic force microscopy (AFM), has 
been shown to be a valuable tool. An AFM consists of a cantilever with a spherical tip 
which can scan the surface of the specimen. Reaching close contact with the specimen, 
forces between the tip and sample will result in deflection of this cantilever, that can be 
detected by changes in reflection of a laser spot. This technique has been previously used 
to measure mechanical stiffness in endothelial cells. However, by comparing endothelial 
cell layers with and without removal of the EG, the presence and stiffness of the EG 
could also be measured. This resulted in an estimated thickness of 400 nm of the EG on 
cultured endothelial cells, with a 50% EG thickness reduction after heparinase treatment 
[42]. Changes in the endothelial surface layer stiffness and thickness were associated 
with both endothelial activation and shedding of syndecan-1 and HA in renal failure 
patients and in animals [43]. 
Exclusion of macromolecules 
Using intravital microscopy, a luminal microdomain that is inaccessible for erythrocytes, 
leukocytes and macromolecules (e.g. 70 kDa dextran, dex70) can be demonstrated. For 
small molecules however, this microdomain is still accessible. When damaging this 
layer, using a 1-2 minute light-dye treatment, erythrocytes and dex70 are able to enter 
this microdomain (figure 5A,B) [44]. In addition to the demonstration of size exclusion, 
this technique can also be used to show the charge exclusion properties of the EG (figure 
5C) [45]. 
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Figure 5: Exclusion properties of the endothelial surface layer in vivo.  A) Intravital microscopic 
image a hamster cremaster muscle capillary. The anatomical diameter of 5.4 μm is clearly larger 
than the red blood cell column width (left pane) or the plasma column width (right pane) labelled 
with fluorescent dextran (70 kD). This is caused by the  endothelial glycocalyx (EG), as it is imperme-
able for Dex70 and RBCs. B) Image of the same hamster cremaster muscle capillary after light dye 
treatment (for methodology see ref [44]). The anatomical diameter of 5.4 μm is the same as the red 
blood cell column width (left pane) or the plasma column width (right pane) labelled with fluores-
cent dextran (70 kD), suggesting a destruction of the EG. C) Anionic sulfated 40 kDa dextran (green, 
left) and neutral 40 kDa dextran (red, middle) in mouse cremaster tissue capillaries. Difference in 
distribution within the same capillary (overlay, right), shows the charge-based exclusion of the an-
ionic dextran from the endothelial surface layer. 
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Most of the techniques developed to estimate the changes in EG are based on this principle. 
Haraldsson et al. used Intralipid, a chylomicron-like suspension of purified soybean oil, 
egg-yolk phospholipids, glycerol, and water to use the physical exclusion properties of 
the EG for determining the EG thickness in TEM. After making electron micrographs 
of capillaries, the location of the lipid drop was identified as central or peripheral (being 
within 200 nm from the luminal endothelial surface) [46]. By comparing the distribution 
of these lipid particles before and after for example adriamycin treatment, changes in EG 
thickness could be estimated [47]. In vivo, a theoretically comparable method was used by 
Smith et al., who looked into the location of flowing microspheres. Using dual-flash epi-
illumination, the velocity of infused fluorescently labelled microspheres was estimated 
in the near wall plasma-rich region of venules before and after light-dye treatment to 
degrade the EG. Using this technique, the theoretically suggested hydraulic resistivity 
of the surface layer was demonstrated [48]. Also, the EG thickness was estimated to be 
0.33-0.44 um, which confirms the measurements by Vink and Duling [44]. 
Tracer dilution technique
Based on their in vivo observations in mice, the group of Vink et al. has mainly 
focused on the development of a method to measure changes in EG in patients. The 
tracer dilution technique was the first technique to estimate the glycocalyx volume. By 
comparing the circulating blood volume, using a glycocalyx impermeable tracer, and 
the total intravascular volume, using a glycocalyx permeable tracer, the total glycocalyx 
volume could be estimated. This concept was first applied when Nieuwdorp et al. showed 
that both acute hyperglycemia and type 1 diabetes mellitus coincided with a reduction of 
the estimated EG volume [49,50]. Unfortunately this technique has the disadvantage that 
it is very time-consuming and invasive to infuse labelled RBCs and Dex40. 
RBC-EC gap and SDF imaging
Based on previous observations of the RBC exclusion zone in animal models, the 
presence of an RBC exclusion zone between the RBC column and the endothelium 
was demonstrated in trans-illuminated hamster cremaster muscle capillaries [51,52]. 
More recently we tested the hypothesis that the EG occupies this RBC-EC gap. When 
comparing the width of the RBC column with the internal anatomical vessel diameter 
as defined by the position of the fluorescent endothelium a decreased RBC-EC gap was 
observed after degradation of the EG with hyaluronidase [41].
In addition, Han et al. demonstrated a decrease in this RBC-EC gap when a leukocyte 
was passing through the capillary. Based on earlier data and a rapid recovery of the 
RBC-EC gap, it was concluded that the passing leukocyte temporarily compresses the 
EG [53].  Consequently, the local EG thickness can be estimated in vivo by measuring the 
difference of the RBC column width before and directly after the passing of a leukocyte. 
This hypothesis was validated when the EG was degraded by oxidized LDL after which 
no change in RBC-EC gap could be observed before and after leukocyte passage [54]. 
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Figure 6: Sidestream darkfield (SDF) imaging to measure the perfused boundary region (PBR) 
in the sublingual capillary bed. A) Recordings from the sublingual capillary bed made with the SDF 
camera (left). Capillaries are automatically recognized and analysed after various quality checks 
(right). Based on the shift in RBC column width in time, the PBR can be calculated.  B)  Model of a 
blood vessel showing the PBR in a healthy situation (left) the endothelial glycocalyx prevents the RBC 
to approach the endothelial cell, thus a small PBR is measured. In a disease situation (right) (40, 
55, 57, 60), or after enzymatical endothelial glycocalyx (EG) breakdown in an animal-model,(41) 
the damaged EG allows the RBCs to approach the endothelium more often. This results in a higher 
variation in RBC column width reflected by a high PBR. ESL: endothelial surface layer/ glycocalyx.
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Using side stream darkfield (SDF) imaging the ability of the RBC to access the EG in the 
microcirculation can be measured. The technique uses light with a wavelength within the 
absorption spectrum of hemoglobin. A connected video camera visualizes the scattered 
light from the illuminated tissue [55]. Using this wavelength, the RBC column of the 
superficial microvasculature can be imaged in vivo. Based on the concept that an RBC 
can penetrate deeper into an instable or damaged EG, variations in RBC column width 
in time can be measured and taken as a proxy for EG accessibility. The intraluminal 
RBC perfused region that is situated in between the median RBC column width and 
unperfused domain of glycocalyx, has been coined the perfused boundary region 
(PBR) (figure 6). Deeper penetration of RBCs into the compromised glycocalyx results 
in increased dimension of PBR. We and others have used this technique to determine 
changes in EG in patients compared to control participants. In these studies, the PBR 
was demonstrated to be associated with microvascular perfusion and to be increased in 
patients with coronary artery disease, sepsis and renal failure [40,56-58].  In addition, 
PBR was also associated with microvascular changes in the retinal vascular bed [59]. A 
recent study, however, failed to demonstrate a distinction between the PBR of a pooled 
group of participants with a variable increased cardiovascular risk profile, stressing the 
need for a better understanding of PBR profiles in different patient subclasses based on 
gender and e.g. ethnic background [60]. Nonetheless, patient studies and the validation 
studies in animal models suggest that measuring the PBR to estimate microvascular risk 
is a promising concept.
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Summary and conclusion
The endothelial glycocalyx is proposed to mediate almost all of the endothelial functions 
and structural or compositional perturbation of this glycocalyx associates with a variety 
of vasculature related pathologies. However, monitoring the EG is challenging, since 
the stability of the layer highly depends on its environment (e.g. blood pressure, loosely 
bound plasma proteins and water). Nevertheless, several imaging methods have been 
developed to study the endothelial glycocalyx over the last decades. Using electron 
microscopy, the presence of the endothelial glycocalyx has been observed in vascular 
tissue. An important remaining future challenge for imaging with electron microscopy 
(but also for other   visualization techniques) is the preservation of the EG without using 
stabilizing perfusion fixation techniques. This would allow staining and dimensional 
quantification of the EG in conventionally processed patient biopsies. 
To study compositional changes in the glycocalyx, at least 3D imaging should be used. 
Nonetheless, to study the exact (compositional) changes within the endothelial glycocalyx 
in more detail, future development of new techniques to analyse GAG sequence and 
modifications  is of crucial importance. For patient studies, non- invasively measuring 
changes in the EG using SDF imaging is an interesting new field. With the current 
techniques changes in EG in severely diseased patients can be detected noninvasively. 
However, further validation and optimization of this technique in healthy and diseased 
situations is needed to clear the way for measuring changes in EG as a risk factor for the 
development of vascular diseases
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Endothelial Glycocalyx and Shear Stress
Abstract
Throughout the vasculature a gel-like layer consisting of proteoglycans, glycosaminoglycans, 
glycoproteins and adsorbed plasma molecules covers the endothelium. Within the 
endothelial glycocalyx (EG) heparan sulfates and hyaluronan have been proposed 
to be the most important functional components. The EG has been demonstrated to 
regulate vascular permeability, transduce shear stress and bind chemokines and growth 
factors. Glycocalyx dimension and composition both have been shown to be crucial 
for endothelial function. We hypothesized that long-term continuous laminar shear 
stress induces changes in the EG composition. For this purpose, human umbilical vein 
endothelial cells (HUVECs) were cultured under flow for 7 days. Using wheat germ 
agglutinin (WGA) and the carbohydrate specific antibodies 10E4 and JM403, we observed 
an increased density and thickness of carbohydrates on top of the endothelium and a 
change in heparan sulfate composition within the endothelial glycocalyx. Furthermore, 
by blocking the JM403 epitope within HS in static conditions, we observed a reduction 
of THP-1 monocyte adhesion upon TNF-α stimulation, confirming the predicted pro-
inflammatory role of the JM403 binding epitope. Consequently, the observed reduction 
in JM403 epitope expression within heparan sulfate suggests that long-term shear stress 
leads to a glycocalyx with anti-inflammatory properties. 
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Introduction
Throughout the vasculature, the endothelium is covered by a membrane-bound glycocalyx 
with adsorbed plasma proteins [1,2]. The membrane bound part of the glycocalyx contains 
glycoproteins, glycosaminoglycans and proteoglycans (PG), i.e. core proteins with long 
side-branches that consist of repeated disaccharide glycosaminoglycans (GAGs). Examples 
of GAGs present in the endothelial glycocalyx are heparan sulfate (HS), hyaluronan (HA) 
and chondroitin sulfate (CS) [2]. 
Heparan sulfate is attached to membrane bound core-proteins such as syndecans 1 
and -4, glypican-1 and versican, forming proteoglycans. Starting with glycosylation at 
serine residues on a core protein, HS and CS GAGs are produced in the Golgi apparatus. 
Here, especially HS is extensively modified. N-Deacetylase/N-Sulfotransferase (NDST) 
modifies the N-acetylglucosamine by N-deacetylation or subsequent N-sulfation, while 
some glucuronic acids are epimerized to L-iduronic acid (IdoA). Hereafter, the sulfation 
pattern of the HS chain is modified by several sulfotransferases, which sulfates C2 of the 
uronic acids and C6 (and rarely C3) of the glucosamine residues. After modification, the 
HSPG is transported to the membrane where it can be modified again by endosulfatases 
(SULF1 and SULF2) and heparanases. In contrast to heparan sulfates, hyaluronan is not 
directly attached to the membrane via a core-protein, but can be bound to hyaluronan 
synthase, CD44, or hyaluronidase. Hyaluronan can also be cross-linked by various 
hyaluronan binding proteins, such as versican, aggrecan, neurocan and tumor necrosis 
factor-stimulated gene 6 (TSG-6), some of which are also able to bind HS [3,4]. This 
interconnected matrix of carbohydrates has been proposed to be involved in almost all 
functions of the endothelial layer, such as inflammation, coagulation, permeability, shear 
sensing and regulation of perfusion [2,5,6]. Perturbation of this layer has been associated 
with cardiovascular disease, sepsis, renal failure and diabetes [5]. 
While HS functions as an interactive matrix for protein interaction, the GAG composition 
is critical for the function of the EG and the underlying endothelium. In particular, 
variation in HS disaccharide sequence and sulfation patterns determines binding 
properties for circulating proteins [7,8]. Binding of growth factors, such as FGF-2 and 
VEGF, or cytokines have been shown to be critically dependent on binding to specific 
sulfated HS moieties, generating gradients (e.g. chemokines) over the endothelium to 
guide cells towards the underlying tissue or concentrate factors near their receptor (e.g. 
growth factors) [9-11]. HS are made up of up to 150 modified disaccharide units, which 
allow for a high variety in binding sites for different proteins [7,9,12]. Consequently, HS 
are involved in many cellular processes such as attachment, migration, differentiation, 
blood coagulation, lipid metabolism, and inflammation [7]. Because the production of 
HS is continuously ongoing and the sulfation pattern can be rapidly modified by enzymes 
such as sulfotransferases and sulfatases, protein binding specificity can be rapidly adjusted 
upon changes in the environment [13,14].
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In vitro, the endothelial surface layer lacks most of its barrier function in cultured 
HUVECs when compared to the in vivo situation [15,16]. In addition, the endothelial 
glycocalyx dimensions observed in vitro are reduced [17]. One of the explanations for 
these differences between in vivo and in vitro is lack of a proper endothelial environment 
during culture [18-20]. Especially, shear stress has been shown to be involved in 
glycocalyx production and function. For example, shear stress has been shown to result in 
incorporation of hyaluronan within the endothelial glycocalyx [21]. In vivo, perturbation 
of the endothelial glycocalyx was observed in areas of disturbed flow, areas that are also 
vulnerable for development of atherosclerosis [22-24]. These findings have been also 
demonstrated in cultured endothelial cells through the exposure to either atheroprone or 
atheroprotective waveforms during prolonged culture and suggest that uniform laminar 
shear stress is beneficial for presence of a healthy endothelial glycocalyx [25].
In this study we hypothesized that prolonged laminar shear stress leads to compositional, 
dimensional and consequently also functional changes within the endothelial glycocalyx. 
To study this, primary isolated human umbilical vein endothelial cells (HUVECs) were 
cultured under continuous laminar flow (shear stress is 10 dyne/cm2) for 7 days. Wheat 
germ agglutinin (WGA) was used to quantify the total amount of carbohydrates on top 
of the endothelial cell. Compositional changes were studied using antibodies against 
different HS moieties (domains). For this we used HS antibodies 10E4 and JM403, 
since the cell-associated HS-epitope necessary for binding is known for both of these 
antibodies: 10E4 mainly binds to mixed HS domains, containing both N-acetylated and 
N-sulfated disaccharide units [26], whereas JM403 binding depends on the presence 
of N-unsubstituted glucosamine [27]. Functional changes within the glycocalyx were 
examined by analyzing the role of the JM403 binding epitope in monocytic THP-1 cell 
adhesion.
3
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Material and methods
Cells
HUVECs were isolated from umbilical cords by perfusion, and 20 minutes incubation, 
with trypsin at 37°C. Freshly isolated HUVECs were cultured on 0.5% gelatin coated  75 
cm2 flasks (Greiner Bio-one) in EGM2 medium (Lonza, Basel, Switzerland) supplemented 
with antibiotics/antimycotics (Life technology, Carlsbad, California, USA) and used for 
experiments at passage 1-3.
Flow experiments
Flow experiments were performed using an ibidi flow system (Ibidi, Martinsried, 
Germany). HUVECs were seeded into closed perfusion chambers (ibiTreat 0.4 µ-Slide I 
or VI, Luer ) at a concentration of 1.5x106 cells per mL. Cells were allowed to adhere for 3 
hours. Hereafter, the chamber was connected to a computer-controlled air pressure pump 
and a fluidic unit with a two-way switching valve. The pump setup allowed pumping of 
16 mL cell culture medium from two reservoirs in a unidirectional way through the flow 
channel over the monolayer of endothelial cells at a constant shear stress of 10 dyne/
cm2. Medium was refreshed after 1 and 4 days of culture. The chamber and the reservoirs 
containing the medium were kept in an incubator at 37°C and 5% CO2. RNA was isolated 
from cells subjected to shear stress in a 0.4 µ-Slide I Luer flow chamber, while the 6 lanes 
of a 0.4 µ-Slide VI Luer were used for immunofluorescent staining experiments.
RNA Isolation and qRT-PCR
Total RNA was isolated from HUVECs cultured in a µ-Slide using Trizol reagent (Life 
Technologies, Carlsbad, California, USA) and isolation kit (Qiagen, Hilden, Germany). 
Reverse transcription was performed using a 5 minute 65°C incubation of 500 ng 
total RNA with deoxyribonucleotide triphosphates (Life Technologies) and oligo(dT) 
(Life Technologies), cDNA was synthesized using M-MLV First-Strand Synthesis (Life 
Technologies), and detection was carried out using SYBR Green Master Mix (Life 
technologies). Levels of expression were determined by normalizing to GAPDH levels.
Cell culture and confocal immunofluorescence microscopy
After static culture (24 hours) or exposure to flow (24 hours or 7 days), HUVECs were 
fixed in freshly made 4% paraformaldehyde in HBSS for 10 minutes, washed twice with 
HBSS (life technologies) and blocked for 30 minutes with 3% normal goat serum (NGS) 
in HBSS. Cells were incubated overnight (16 hours) at 4°C with 10 µg/mL TRITC-labeled 
wheat germ agglutinin (WGA) (Sigma-Aldrich, St Louis, MA, USA), Hoechst 33528 
(Sigma-Aldrich, 1:5000) and one of the primary antibodies (at 10 µg/mL): 10E4 (Amsbio), 
JM403 (kind gift of dr. van der Vlag, Radboud University Medical Centre, Nijmegen, 
The Netherlands), eNOS (BD bioscience), VE-cadherin (BD bioscience), phalloidin-
rhodamine (Sigma-Aldrich), or the appropriate control IgM or IgG isotype antibodies 
diluted in HBSS. After washing three times with HBSS, cells were incubated with a 
secondary antibody for 1 hour (2 µg/mL of anti-mouse IgM-Alexa488 or anti-mouse IgG-
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Alexa488). Cells were again washed for three times with HBSS and imaged using a Leica 
SP5 confocal microscope and a 63x (N.A. 1.4) objective.
Mononuclear cell adhesion assays
Mononuclear THP-1 cell adhesion assay was performed as published previously with 
some modifications [28]. In short, HUVECs (1.5x106 cells/mL in EGM2 medium) were 
seeded into closed perfusion chambers (ibiTreat 0.4 µ-Slide VI Luer). After 24 hours of 
static culture the monolayer of endothelial cells was stimulated with TNF-α (10 ng/ml) for 
5 hours. Cells were washed with HBSS containing 1% BSA cells and incubated with either 
JM403 or IgM isotype control (both 10µg/mL) for 1 hour at room temperature. Next, flow 
chambers were positioned on an inverted microscope (Leica AF6000) and attached to a 
syringe pump to perfuse the endothelial monolayer with THP-1 monocytes (5x105 cells/
mL in HBSS + 1% BSA). THP-1 cells were perfused over the EC layer for 5 minutes at 0.5 
dyne/cm2 after which the monolayer was washed with HBSS + 1% BSA for 5 minutes. Flow 
chambers were imaged at 10 different locations. All images were taken at the centerline of 
the flow chamber. The number of adherent cells per field of view was quantified using the 
public domain National Institutes of Health IMAGE program (ImageJ, available at http://
rsb.info.nih.gov/nih-image).
CLSM image analysis and quantification
Confocal 12-bit gray-scale axial image stacks (xyz dimensions, 0.08×0.08×0.13 μm) that 
covered 6724 μm2 of surface area per image and a height of 5 to 10 μm above the EC 
nuclear plane were recorded using LAS-AF image software (Leica). The image stacks were 
analyzed using ImageJ software. For the luminal endothelial glycocalyx quantification, 
first the nuclear and peri-nuclear area was selected, to exclude the cell area in which 
the cell thickness was too thin to differentiate between luminal and abluminal staining. 
Thickness of the WGA stained layer was estimated within this area of interest, between 
the peak nuclear (Hoechst) signal and the luminal end of WGA fluorescence, designated 
as twice the background signal. Next, total luminal WGA signal of the 3 dimensional area 
of interest was calculated from the sum of average fluorescence in every z-plane within 
this area. In addition, heterogeneity in WGA distribution was determined by calculating 
the coefficient of variance between these planes. To quantify specific staining for the HS 
moiety antibodies, total isotype control (IgM) signal was subtracted from the total 10E4 
or JM403 signal. A visualization of this method is shown in figure 1.
Statistical analyses 
Data are presented as mean ± SEM, unless stated otherwise. To exclude variations due 
to technical differences between the experiments, fold change of staining intensity and 
coefficient of variances were shown relative to the static control group. Differences between 
the groups were tested by analysis of variance (ANOVA). Differences were considered 
statistically significant if p<0.05. Data analysis was performed using SPSS version 20.0 
(SPSS Inc, Chicago, IL) and GraphPad Prism, version 5.0 (GraphPad Prism Software Inc, 
San Diego, CA).
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Figure 1: Methods to quantify the luminal endothelial glycocalyx stainings. A) Method to quantify 
the luminal glycocalyx. Example of endothelial glycocalyx stained with wheat germ agglutinin 
(WGA), 10E4 and Hoechst. White box shows the area of interest which should be quantified (upper). 
B) Example of endothelial glycocalyx stained with wheat germ agglutinin (WGA), IgM isotype 
control and Hoechst. Total signal within the white box was subtracted from total signal of the HS 
staining to control for non-specific staining. C) Example of quantification method. Peak of Hoechst 
signal determines the lower border of the area of interest (left). 2x WGA background signal is used 
to determine the upper border of the area of interest (middle). Total area under the curve of the 
area of interest is used to determine the total luminal signal. Thickness of area of interest is used to 
determine dimensions of WGA signal.
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Results
Prolonged laminar flow leads to a quiescent monolayer of HUVECs
HUVECs were cultured under a laminar flow of 10 dyne/cm2 for 7 days to confirm the 
ability to induce a quiescent endothelial phenotype.(20) First, the effect of prolonged 
shear stress on endothelium was tested by analyzing cell morphology and expression of 
shear responsive genes and proteins. After 7 days at 10 dyne/cm2, shear stress sensitive 
genes Krüppel-like Factor 2 (KLF2) and endothelial nitric oxide synthase (NOS3) were 
up regulated compared to static cultured cells (14.1% to 1.7%, p<0.05 for KLF2 and 8.9% 
to 2.3%, p<0.01 for eNOS, relative to GAPDH expression respectively). In contrast, gene 
expression of the inflammatory markers E-selectin and IL-8 decreased after 7 days of flow 
culture (figure 2). The inflammatory marker IL-8, however, dramatically increased after 
24 hours of culture under flow (0.2% to 24.2% of GAPDH expression levels, static vs. 
flow 24hrs, respectively), which confirms previous data showing an acute inflammatory 


















Figure 2: Effects of prolonged shear stress on gene expression of shear responsive genes. Gene 
expression as percentage of GAPDH expression after static, 1 day flow and 7 days of flow culture for 
KLF2, eNOS, E-selectin and IL-8.
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In addition, typical short F-actin shear fibers and alignment to the direction of the flow was 
observed after the prolonged shear culture [30] and VE-cadherin and eNOS expression 
both were increased and robustly expressed at the cell-cell contacts (figure 3).
Laminar shear stress induces a thicker glycocalyx 
Next, we tested our hypothesis that this prolonged exposure leads to changes in endothelial 
glycocalyx production and composition. For this, we stained the EC after indicated time 
periods with the N-acetylneuraminic acid and N-acetyl-β-D-glucosamine binding lectin 
WGA and the specific HS-binding antibodies 10E4 and JM403. After 7 days of exposure 
to 10 dyne/cm2 shear stress, total intensity of WGA staining was significantly increased 
compared to static conditions (1.49 fold increase, p<0.05) (figure 4). EG thickness was also 
increased after 7 days of shear stress compared to both 24hrs of static culture and 24hrs 
of shear stress (3.10 vs 2.52 and 2.61 µm respectively, p<0.01 and p<0.05). Besides this 
notable increase in WGA intensity and thickness, a more homogeneously distributed layer 
was observed (reflected by the lowest coefficient of variance: 0.84 fold change compared to 
24hrs of static culture, p<0.05).













Figure 3: Cells change upon prolonged shear stress culture. HUVECs are stained with antibodies 
against VE-cadherin (upper) and eNOS (middle) and the F-actin binding phalloidin-rhodamine 
(lower) to visualize endothelial phenotypic changes. Static cultured HUVECs (left) were compared 
to HUVECs cultured for 7 days at a shear stress of 10 dynes/cm2.
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Laminar shear stress induces a change in enzymes involved in glycocalyx modification.
Production and composition of the endothelial glycocalyx are determined by the presence 
and activity of several enzymes. Changes in each of these enzymes can results in functional 
changes of the endothelial glycocalyx. To determine whether the composition of heparan 
sulfates within the endothelial glycocalyx could be changed by changes in gene expression 
upon shear stress, gene expression levels of enzymes involved in HS sulfation pattern 
modification were studied. Seven days of flow exposure did not alter N-deacetylase/N-










































Figure 4: Prolonged shear stress increseses WGA thickness and density on top of HUVECs. 
A) Representative examples of WGA staining on top of the endothelial cells. White box shows the 
zoomed area (right). B) Quantification method described in figure 2 was used for the stainings in 
A). Within the area of interest the total intensity (left), thickness of the stained area (middle) and 
distribution on top of the endothelium (right) was measured.
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Nevertheless, the intracellular HS-chain modifying heparan sulfate sulfotransferases 
(HS2ST1, HS3ST1 and HS6ST1) were variably changed upon shear stress stimulation. 
In addition, the extracellular modifying enzymes 6-O-endosulfatase 1 and 2 (SULF1, 
SULF2) and heparanase (HPSE1) were all increased upon 7 days of shear stress (figure 
5). Next to enzymes involved in heparan sulfate production, the gene expression of the 
hyaluronan synthesizing enzyme HAS2 was increased after prolonged shear stress (no 
changes were observed for HAS1 or HAS3) and was accompanied by an increase in the 

















Figure 5: Prolonged shear stress alters gene expression of enzymes involved in HS and HA 
production and modification. Gene expressions as percentage of GAPDH expression after stat-
ic, 1 day flow and 7 days of flow culture for the genes coding for enzymes involved in HA produc-
tion (HAS2) and breakdown (HYAL) and HS sulfation pattern modification (HS2ST1, HS3ST1, 
HS6ST1, SULF1, SULF2) and breakdown (HPSE).
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Prolonged Shear stress induces changes in luminal heparan sulfate composition
The HS modifying enzyme gene expression indicates that the chain is compositionally 
altered upon prolonged shear stress. This was tested further using binding of antibodies 
against two different HS domains. The expression of specific HS domains was studied 
after 1 and 7 days of shear stress and was compared to static control conditions. For this 
purpose, two antibodies against HS domains (JM403, 10E4) were used. Interestingly, total 
JM403 signal was significantly increased after 1 day of culture under shear stress (total 
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Figure 6: Prolonged shear stress alters the expression of heparan sulfate domains. A) Repre-
sentative examples of HS staining on top of the endothelial cells with JM403 (left) and 10E4 (right) 
after static, 1 day flow and 7 days of flow culture. B) Quantification of staining with specific HS-
domain antibodies JM403 (left) and 10E4 (right). For quantification, isotype control staining is 
subtracted from the stainings shown in figure 6A.
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However, after 7 days of flow the total luminal staining signal was markedly reduced 
for JM403 compared to both static culture and 1 day shear stress (total signal intensity 
of 6786 ± 5022, p<0.05) (figure 6). In contrast, total 10E4 signal was not significantly 
changed, although a trend towards a reduction could be observed during 7 days of flow. 
Both antibody expression levels thereby suggest that exposure to shear stress results in 
the modification of the luminal heparan sulfate composition in HUVECs bearing less 
N-substituted residues
Laminar shear stress induces an anti-inflammatory glycocalyx
Both JM403 and L-selectin have been previously shown to require the presence of 
N-unsubstituted glucosamine residues to bind to HS [27,31]. Consequently, we predicted 
that the JM403 epitope could be a pro-inflammatory HS domain. In our study, this would 
imply that the increase in JM403 after 24 hours and the decrease after 7 days flow, reflect a 
pro- and anti-inflammatory phenotype, respectively. To study this hypothesis, the capacity 
of the JM403 epitope to mediate monocyte recruiting and adhesion was tested. For this 
purpose, static cultured HUVECS were stimulated with TNF-α to enable inflammatory cell 
adhesion. Consequently, these cells were perfused with THP-1 monocytes. To determine 
the role of the JM403 epitope in adhesion, the assay was performed after blocking the 
epitope with JM403 antibodies or an appropriate isotype control. Blocking the JM403 
domain on the endothelial cell surface with JM403 antibody specifically reduced adhesion 
of the mononuclear THP-1 cells (71.7% of control adhesion, p<0.01) (figure 7). 
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Figure 7: Monocyte adhesion after blocking the JM403 epitope in cultured HUVECs. A) Exam-
ples of monocytes adhered to the endothelial layer after blocking with JM403 (right) and a control 
IgM antibody (left). B) Quantification of A. Number of adhered monocytes where corrected after 
blocking for JM403 were corrected for the number adhered in the control situation.
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Discussion:
Changing the endothelial environment in vitro through exposing the cells to a prolonged 
uniform laminar shear stress not only induces a more homogeneously distributed and 
thicker glycocalyx but also changes heparan sulfate composition of surface expressed 
HSPG leading to a non-inflammatory, non-adhering phenotype.
While previous studies already have suggested a role for shear stress in expression and 
function of an endothelial glycocalyx [21,25,32,33], we focused in this study on the 
compositional and functional changes in the luminal endothelial glycocalyx upon 
exposure to long-term shear stress. To quantify the luminal stained endothelial glycocalyx 
we reconstructed this layer to a 3-dimensional image to properly distinct luminal from 
abluminal staining. In contrast to the observed effects of long-term shear stress exposure, 
we confirmed with the observed increase in IL-8 levels after 24 hours of shear stress 
previous data that short-term exposure to high laminar shear stress evokes a profound 
inflammatory response in endothelial cells instead of inducing a quiescent phenotype [29]. 
Furthermore, the subsequent decrease in IL-8 after 7 days reveals that prolonged exposure 
to such shear stress induces the quiescent phenotype, as exemplified by induction of the 
well-known shear-responsive genes, such as KLF2 and eNOS. Together, with rearranging 
of VE-cadherin and eNOS proteins into cell-cell contacts and the appearance of typical 
short stranded f-actin filaments at the abluminal endothelial domain.
After subjecting the cells to shear stress we observed an increase in WGA staining 
intensity and thickness after 7 days. WGA binds N-acetyl-D-glucosamine which enables 
us to estimate changes in the endothelial glycocalyx dimensions, since this carbohydrate 
is present in most of the glycocalyx components (except for chondroitin and dermatan 
sulfate). Interestingly we also observed a more homogeneous distribution of the WGA 
staining on top of the endothelial layer. Previously a decrease of WGA staining was 
observed upon stimulating endothelial cells with ROS [34]. Furthermore, WGA staining 
on endothelial cells in rat glomeruli was decreased in a model of spontaneous kidney 
failure in aged rats [35]. 
Since WGA stains most of the subcomponents of the endothelial glycocalyx, the biochemical 
composition of the glycocalyx cannot be studied directly using this lectin. Since the 
specific composition could be crucial for endothelial cell function we used the following 
HS-domain specific antibodies 10E4 and JM403. While 10E4 mainly recognizes mixed HS 
domains that contains both N-acetylated and N-sulfated disaccharide units [26], JM403 
typically needs the relatively rare N-unsubstituted glucosamine residues within the HS 
chain to be able to bind [27]. The presence of this N-unsubstituted domain within the HS 
sequence mostly likely depends on the activity and efficiency of the NDST enzymes. These 
enzymes modify the HS sequence during the modification process by substituting the 
acetyl group from glucosamine residues with sulfate, via an N-unsubstituted intermediate. 
However, sometimes this modification is partial, which then results in N-unsubstituted 
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domains in mature HS [36-38]. Since under normal, healthy, circumstances this domain 
occurs relatively rare, it has been proposed that due to pathological processes this domain 
contributes to selective protein, and or receptor binding [39].  
To the best of our knowledge, we are the first to study the specifically luminal expressed 
JM403 epitope in HS, since most studies only investigated JM403 binding within the 
ECM. Interestingly, JM403 staining was significantly increased after 24 hours. After 7 days 
of shear culture, hardly any JM403 staining was observed. The observed increase after 1 
day coincided with a pro-inflammatory phenotype, since IL-8 expression was 100–fold 
increased. This might imply a relation between the JM403 epitope within HS and a pro-
inflammatory endothelial phenotype. The observation that this epitope for JM403 binding, 
a domain with N-unsubstituted glucosamine residues, is involved in THP-1 adhesion 
further supports this hypothesis. Since it has been shown that endothelial HS that are 
able to bind L-selectin are enriched for N-unsubstituted glucosamine residues [31], the 
observed reduction in monocyte adhesion might be L-selectin dependent. In addition to 
the quiescent endothelial phenotype, this indicates that prolonged shear stress induces an 
anti-inflammatory HS modification. In contrast, a short period of shear stress leads to a 
pro-inflammatory phenotype of the cell (high Il-8 gene expression) and glycocalyx (high 
JM403 staining).
Although the changes in EG are clearly observed after 7 days of shear stress culture, we 
cannot be sure that shear stress is the single responsible stimulus. Prolonged culture 
of endothelial cells under static conditions has been shown previously to also induce 
endothelial glycocalyx growth [40]. However, when endothelial cells were cultured under 
static conditions for 7 days, they slowly continued to proliferate and eventually formed 
several cell layers without any organization. This made it practically impossible to compare 
the glycocalyx on top of 7 days cultured cells in static conditions with the monolayer in 
flow conditions (data not shown). 
Altogether we demonstrated that prolonged fluid shear stress alters the composition and 
structure of the endothelial glycocalyx. Shear stress induces the production of a thicker and 
more homogeneously distributed layer which. Furthermore, the altered HS composition 
results in the decrease of the epitope for JM403 binding, which is indicative for a more 
anti-inflammatory endothelial glycocalyx upon prolonged shear stress stimulation.
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Abstract
Glomerular endothelium is highly fenestrated and its contribution to glomerular barrier 
function is therefore subject of debate. In recent years a polysaccharide rich endothelial 
surface layer (ESL) has been postulated to act as filtration barrier for large molecules 
such as albumin. To test this hypothesis we disturbed the ESL in C57Bl/6 mice using 
chronic hyaluronidase infusion during 4 weeks, and monitored albumin passage using 
immunolabeling and correlative light-electron microscopy, that allows for complete and 
integral assessment of glomerular albumin passage. ESL ultrastructure was visualized by 
transmission electron microscopy using cupromeronic blue and by localization of ESL 
binding lectins using confocal microscopy. We demonstrate that glomerular fenestrae are 
filled with dense negatively charged polysaccharide structures which are largely removed 
in the presence of circulating hyaluronidase, leaving the polysaccharide surfaces of other 
glomerular cells intact. Both retention of cationic ferritin in the glomerular basement 
membrane and systemic blood pressure were unaltered. Enzyme treatment, however, 
induced albumin passage across the endothelium in 90% of glomeruli, while this could 
not be observed in controls. Yet, there was no net albuminuria due to binding and uptake 
of filtered albumin by the podocytes and parietal epithelium. ESL structure and function 
completely recovered within 4 weeks upon cessation of hyaluronidase infusion. Thus, the 
polyanionic ESL component hyaluronan is a key component of the glomerular endothelial 
protein permeability barrier.
4
70    71
Introduction
The glomerular endothelium is highly fenestrated and its pores are estimated to be around 
60-80 nm in diameter. While fenestrae may facilitate the formation of high volumes of 
ultrafiltrate, it would also imply loss of macromolecules such as albumin, as suggested by 
intravital microscopy studies [1]. In vivo, endothelium is covered with a polysaccharide-
protein gel-like structure, the glycocalyx, or endothelial surface layer (ESL). The 
composition and biological activity of this surface layer can widely differ in a tissue-
specific manner. The main constituents of the ESL are protein cores, typically syndecans, 
with large heparan sulfate side chains (+/- 60 %) or chondroitin sulfate (+/- 15 %) [2]. 
In addition, plasma proteins such as albumin and orosomucoid bind to these negatively 
charged proteoglycans and glycosaminoglycans [3]. Hyaluronan integrates into this gel like 
a mesh, anchoring to CD44 on the cell membrane [4]. Hyaluronan consists of repeating 
disaccharides composed of N-acetylglucosamine (GlcNAc) and glucuronic acid (GlcA) 
and is the largest polysaccharide found in vertebrates. Together these polysaccharides 
form a very active biologically surface layer, which may stretch out up to 500 nm into the 
vascular lumen [2]. Many growth factors such as fibroblast growth factor (FGF), vascular 
endothelial growth factor (VEGF), and circulating complement inhibitors such as factor 
H, require prior engagement with this surface layer before they can interact with their 
functional ligands [5-7]. Heparan sulfate repeats can also activate antithrombin-III, and 
bind extracellular superoxide dismutases, while after activation of the endothelial cell they 
function as receptors for platelet and leukocyte adhesion [8-12]. The pivotal role of the 
ESL is illustrated by the fact that up to now no successful genetic mice models could 
be generated where structural polysaccharide components of the ESL are lacking. These 
properties have put the ESL in the center of interest as a modulator of endothelial cell 
function. The ESL has also been postulated to act as a barrier against albumin filtration. 
The combination of negatively charged heparan sulfates and the mesh like structure of the 
less charged hyaluronan may theoretically prevent albumin filtration through the fenestrae 
[13]. In fact, it could be demonstrated that the Frank Starling filtration equilibrium in 
non-renal microvasculature is generated by the inability of albumin to permeate the ESL 
and its resulting oncotic gradients over this layer [14]. Moreover, acute infusion of high 
dosages of enzymes that degrade the ESL results in increased fractional albumin clearance, 
extrapolating this concept also to the kidney [15,16].
In the current study we explore the effects of chronic disruption of the ESL on albumin 
filtration over the glomerular endothelium and the possible effects on glomerular 
morphology. To this end, we use a new electron microscopy technique that allows 
visualization of the ESL and albumin transport within the entire glomerular section 
at nanometer resolution [17]. To study the functional role of the ESL with respect to 
prevention of albumin filtration, it was perturbed by chronic low dose infusion of 
hyaluronidase, a hyaluronan degrading enzyme, which has been shown to increase the 
permeation of the ESL, for example in the cremaster muscle [13].
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Material and methods
All materials are from Sigma-Aldrich (St. Louis, MO, USA) or stated otherwise.
Mice and experimental groups
Experiments were performed using C57Bl/6 mice (B6, Charles River, France) at 14 
weeks of age. Mice were randomly divided into 2 groups and implanted with an osmotic 
minipump (Alzet, Cupertino, CA, USA) containing hyaluronidase (group 1, total n = 26) 
or inactivated hyaluronidase (group 2, total n = 22). 
Anesthesia during surgical procedures was performed using i.p. injection of 0.2 ml of a 
cocktail of midazolam (1 mg/mL, Roche Nederland B.V., Woerden), dexmedetomidine 
(50 μg/mL, Orion corporation, Espoo, Finland) and fentanyl (10 µg/mL, Hameln 
pharmaceuticals gmbh, Hameln, Germany) in H2O.  After 4 weeks, 6 mice from each 
group were sacrificed, the pumps of 6 additional mice per group were removed and 
these animals were allowed to recover for an additional 4 weeks. In a subset of control 
B6 mice (n = 2) and B6 mice with an osmotic minipump containing hyaluronidase for 4 
weeks (n = 3), the glomerular ESL was stained using cupromeronic blue. In addition, 14 
weeks-old B6 mice received an osmotic minipump containing various concentrations of 
hyaluronidase for 2 weeks to determine the optimal concentration (n = 15) or an osmotic 
minipump containing either hyaluronidase (n = 8) or inactivated hyaluronidase (n = 5) 
for 2 weeks for blood pressure measurements. All animals had free access to food and tap 
water. The experimental protocol was approved by the local Animal Ethical Committee 
of Maastricht University (hyaluronidase concentration determination and blood pressure 
measurements) and Leiden University (others). All animal work was performed in 
compliance with the Dutch government guidelines.
Hyaluronidase solution
Bovine testicular hyaluronidase (100 U/µL in saline) was injected into an osmotic 
minipump, which releases its content at a rate of 0.25 µL/hr (25 U/hr), into the right 
jugular vein for 4 weeks. The effect of protease contamination of the hyaluronidase 
solution is negligible after infusion into the circulation (data not shown). In a subset of 
animals, concentrations of 40 U/µL (10 U/hr), 100 U/µL (25 U/hr) and 400 U/µL (100 U/
hr) in saline were used and released into the right jugular vein for 2 weeks. In parallel, 
heat-inactivated hyaluronidase (boiled for 30 minutes at 90°C, resuspended by vortex) 
was used as control [18].  
Systemic tracer dilution determination
At 16 weeks of age, distribution volume determinations of labeled erythrocytes and 40 kDa 
high molecular weight dextrans were performed to assess systemic vascular red blood cell- 
(Vrbc), plasma- (Vplasma), ESL- (Vglx) and total vascular volume (Vtotal) as previously described 
[21]. Short-term hyperglycemia increases ESL permeability and acutely decreases lineal 
density of capillaries with flowing red blood cells [22]. In brief, RBC were labeled with 
carboxyfluorescein diacetate, succinimidyl ester (CFSE, Invitrogen) and mixed with a 
4
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stock solution (10 mg/mL) of 40 kDa Texas Red labeled dextran. Following intravenous 
injection of 0.1 mL of this tracer mix, blood samples were drawn at 2, 5, 10, 15, 20 and 30 
minutes. Capillaries were centrifuged, Ht was determined and plasma was stored at -20°C. 
Circulating labeled RBC fraction was determined using flow-cytometry (FACSCalibur; 
Becton Dickinson). Circulating Vplasma was calculated using the following formula: ([1 
– Ht] x Vrbc)/Ht [23,24]. In each plasma sample, fluorescence was measured at 610 nm 
(D40-TR) using a spectrofluorophotometer (VICTOR; Perkin-Elmer, the Netherlands). 
Concentration-time curves of D40-TR were fitted with a mono-exponential function to 
determine initial tracer distribution volume. 
Non-invasive tail blood pressure measurement
Blood pressure (BP) was measured in conscious animals using the tail-cuff method (CODA-
2, Kent Scientific, Torrington, CT). Briefly, each session consisted of 5 acclimatization 
cycles followed by 15 BP measurements cycles. On the data collection day, 2 sessions of 
15 BP measurements were obtained; a set was accepted if the computer identified >50% 
successful readings. The average from one session was used for systolic BP (SBP), diastolic 
BP (DBP), mean BP and heart rate in each individual mouse.
Urine collection and analysis
Mice were kept in metabolic cages for 24 hours two days before pump implantation and 
two days before the end of the experiment (week 0 and week 4 or 8). Mice from the recovery 
groups were kept additionally in metabolic cages two days before pump removal (week 4) 
and two weeks before perfusion fixation (week 6). Urine was centrifuged and subsequently 
stored at −20°C. Rocket immuno-electrophoresis was used to quantify albumin levels in 
urine (protocol modified from Tran et al.) [19]. Urine creatinin levels were determined 
by a kinetic colorimetric assay using a commercially available kit (Creatinin Jaffé method, 
Roche diagnostics) and a Cobas Integra 800 analyzer (Roche Mannheim, Germany). 
Protein levels were determined by the TPUC3 protocol using a Cobas C analyzer (Roche 
Diagnostics, Mannheim, Germany).
Tissue preparation
A subset of mice received, 15 minutes before the induction of anesthesia (see above), 200 µL 
of ferritin (equine spleen, 25 mg/ml) via the tail vein. In anesthetized mice the abdominal 
aorta was exposed and cannulated distal to the renal arteries. The right renal artery was 
ligated at the renal stalk and immediately fixated by injecting 2% paraformaldehyde (PFA) 
in PBS before removal of the kidney. The kidney capsule of the unperfused excised right 
kidney was removed and kidney was cut in half. One half was fixated overnight at 4°C 
in 2% PFA in PBS for detection of endogenous albumin and  lectins), the other half was 
placed in 1.5% glutaraldehyde (GA) and 1% PFA in PBS overnight at 4°C  for detection of 
ferritin (see below). From 6 additional mice, 3 were treated with active and 3 with inactive 
hyaluronidase for 4 weeks. Both kidneys, unperfused, were isolated directly and snap-
frozen in liquid nitrogen for immunohistochemistry.
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Detection of endothelial surface layer
For electron microscopic illustration of ESL in the glomerulus, the left kidney was perfused 
with 0.1% BSA and 5 U/ml heparin in HBSS at 2 mL/min to remove blood followed by 
0.05% cupromeronic Blue (CB) in sodium acetate buffer (25 mM, pH 5.8) containing 
1.5% GA, 1.0% PFA and 25 mM MgCl2 for 5 minutes at 2 mL/min. After excision of the 
left kidney, the capsule was removed and the kidney was sliced in small tissue samples (» 
2 mm3) and incubated overnight at 4°C in the fixation solution containing CB as above. 
These CB stained samples were washed twice in sodium acetate buffer (25 mM, pH 5.8) 
and incubated for 1 hour in 0.5% phospho-tungstic acid in 50% ethanol. Samples were 
further dehydrated and embedded in epon. Transmission electron microscopy (TEM) 
data were collected on a Tecnai 12 (BioTWIN) from 100 nm sections as above, using the 
same settings.
Correlative microscopy for detection of endogenous albumin
Kidney tissue was dissected at 100 µm thickness with a vibratome (Leica Microsystems 
B.V., Rijswijk, the Netherlands). Part of the slices are blocked with 10% normal goat serum 
and 0.3% Triton 100 in PBS for 30 minutes on ice followed by incubation o/n at 4°C with 
horseradish peroxidase-conjugated goat anti-mouse albumin (Bethyl Labs, USA, diluted 
to 1/400) in 1% heat inactivated normal goat serum in PBS. After washing about 1mL of 
3,3’-diaminobenzidine reaction solution (15 mL DAB solution + 10-15 μL H2O2, 30%, 
(Dako, Denmark)) was added, incubated for 30 minutes at 4°C, washed again and incubated 
for 1 hour with 1.5% GA and 1% PFA in cacodylate, rinsed in cacodylate and postfixated 
in 1% osmium tetroxide + 1.5% potassium ferrocyanide. Samples were dehydrated and 
processed further into epon. Sequential 100 nm sections were mounted on a copper slot 
grid covered with Formvar support film and a 3 nm carbon coating for TEM, and on a 
water drop on a clean glass slide for reflection contrast microscopy (RCM).20 The sample 
was mounted with immersion oil (Immersol 518F, Zeiss) on a RCM-adapted microscope 
(reflection contrast device RV; Leica, Wetzlar Germany). Images were recorded with a 
100×, 1.25 NA objective. TEM sections were stained with an aqueous solution of lead 
citrate and uranyl acetate before visualization and data was collected at an acceleration 
voltage of 120 kV, on a Tecnai 12 (BioTWIN) transmission electron microscope, equipped 
with an Eagle CCD camera (FEI company, Eindhoven, the Netherlands). 
Ultrastructural large scale virtual slides 
To place the presented high power magnification images in their proper context, additional 
online ultrastructural large scale virtual slides are provided (CCDB database website URL) 
as described previously by Faas et al. [17]. The virtual slides for the samples were recorded 
using automated data acquisition and stitching software with 25,740x magnification at 
the detector plane, corresponding to 1.2 nm pixel size at the specimen level. This results 
in a slide with an overview of the glomerulus, in which you can zoom in into high detail. 
Using this correlative microscopy approach the DAB precipitate can be visualized both 
with RCM and TEM. While RCM allows for the screening of large numbers of glomeruli 
from kidneys from different mice, TEM enables to localize the DAB precipitation at high 
resolution [17].
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Confocal Microscopy
Remaining kidney tissue slices (see albumin staining) were washed twice with HBSS 
(Gibco) containing 0.5% BSA, 5mM HEPES and 0.03 mM EDTA (HBSS-BSA). Slices were 
stained overnight with 10 μg/mL of various fluorescently labeled lectins, i.e. Lycopersicon 
esculentum (LEA-FITC), Bandeiraea simplicifolia (BSI-TRITC) or Triticum vulgaris 
(WGA-TRITC ) or 5 μg/ml monoclonal mouse anti-mouse CD31 antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) in HBSS-BSA and after a brief wash, with Alexa 
Fluor 488 or Alexa 568 conjugated goat anti-mouse IgG (10 μg/mL, Molecular Probes, 
Grand Island, NY, USA). Slices in HBSS-BSA were fixed to the bottom of a petridish and 
were examined using a CLSM (710-NLO; Carl Zeiss, Göttingen, Germany) and a 40x 
objective lens (Plan Neo Fluar NA 1.3/oil DIC; Carl Zeiss). Confocal 12-bit gray-scale axial 
images (xy dimensions, 100×100μm) of the glomerulus were recorded using ZEN-2009 
Image software (Carl Zeiss). The images were analyzed with the public domain National 
Institutes of Health IMAGE program (available at http://rsb.info.nih.gov/nih-image). For 
each image, amount and location of intensity profiles were quantified by calculating the 
distance from the peak of the CD31 signal to the half-width of the intra- or extra luminal 
lectin signal along a line of interest.
Detection of ferritin particles
Kidney samples fixated overnight at 4°C in 1.5% GA and 1% PFA in PBS were dissected 
at 100 µm thickness with a vibratome. Slices were washed with PBS and 0.1 M sodium 
cacodylate buffer, incubated for 1 hour with 1.5% GA and 1% PFA in sodium cacodylate 
buffer, rinsed in sodium cacodylate buffer and postfixated in 1% osmium tetroxide and 
1.5% potassium ferrocyanide. Samples were dehydrated and processed further into epon. 
TEM data were collected at an acceleration voltage of 120kV on a Tecnai 12 (BioTWIN).
Immunohistochemistry
Frozen kidney sections (2 µm) were fixated in 2% PFA /0.3% Triton X-100 (TX-100) in 
PBS for 10 minutes, washed in PBS and blocked for 30 minutes at room temperature 
in 2% fetal calf serum (FCS; Bodinco, Alkmaar, The Netherlands), 2% bovine serum 
albumin (BSA) and 0.2% fish gelatin (Amersham Biosciences, Buckinghamshire, UK) in 
PBS. Sections were incubated for 45 minutes with primary antibodies (1-10 μg/ml) against 
mouse synaptopodin (Progen Biotechnik GmbH, Heidelberg, Germany), nephrin (R&D 
Systems Europe Ltd., Abingdon, United Kingdom) or desmin (Tebu-Bio, Heerhugowaard, 
The Netherlands) Subsequently, sections were rinsed, incubated for 45 minutes with the 
Alexa 488 or 594-conjugated secondary antibodies (5 μg/mL; Life Technologies Europe 
BV, Bleiswijk, The Netherlands). Finally, sections were rinsed with PBS, postfixated with 
1% PFA in PBS and embedded in VectaShield mounting medium H-1000 (Brunschwig 
Chemie, Amsterdam, The Netherlands). The staining intensities of antibodies were scored 
in 50 glomeruli on a 0-10 scale (0 = no staining, 1 = 10% staining intensity of podocytes, 
10 f= 100% staining intensity). Differences between groups were determined by Mann-
Whitney U testing using GraphPad Prism, version 5.0 software (GraphPad Software, Inc., 
San Diego, CA). P values < 0.05 were considered as significant.
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Statistical analysis
Results are all presented as mean ± SD, morphometric data are given as mean ± SEM. 
Differences between groups were determined by Mann-Whitney U testing using 
GraphPad Prism (GraphPad Software, Inc., San Diego, CA). A p-value of < 0.05 was 
considered statistically significant.
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Results
Hyaluronidase infusion degrades the glomerular endothelial surface layer 
Since complete removal of the ESL in vivo can result in massive thrombosis and 
instantaneous vessel occlusion, we aimed for a partial degradation to study the early 
effects of ESL loss on glomerular permeability properties. An osmotic minipump filled 
with bovine testicular hyaluronidase was implanted together with a catheter into the right 
jugular vein, to chronically degrade hyaluronan from the ESL within the murine blood 
circulation. While a concentration of 100U/hr resulted in massive vascular occlusions and 
poor prognosis within a week (data not shown), a concentration of 25U/hr resulted in 
about 50% reduction in systemic ESL volume after two weeks (figure 1A), as measured 
by the change in distribution volume of 40kDa dextrans, which can freely access the ESL, 
minus the distribution volume of labeled erythrocytes, which cannot access to the ESL. 
No behavioral changes, weight-loss or significant changes in blood pressure or heart rate 





















Figure 1: Effect of hyaluronidase on vasculature. A, Dose-response of ESL volume in mice after 2 
weeks of treatment with 0, 10, 25 or 100 U of hyaluronidase released per hour. Change in ESL volume 
was assessed by means of non-parametric Mann-Whitney U test. *P < 0.05 vs. control. B, Systolic- and 
diastolic blood pressure (left, middle) and heart-rate (right) at the start, during- and at the end of the 
hyaluronidase treatment for two weeks. Change in blood pressure and heart-rate was assessed by means 
of non-parametric Mann-Whitney U test. P = not significant.
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Figure 2: Fluorescent images of lectin stained glomeruli. A, Cross sectional average intensity 
projection of a murine glomerulus, stained with fluorescein-labeled lectins Lycopersicon esculentum 
(LEA-FITC) or Triticum vulgaris (WGA-TRITC) and merged projection. B, Example of fluorescence 
intensity plots explaining localization and quantification of lectin staining according to the endothelial 
cell position (marked with anti-CD31 antibody). Intraluminal localization is calculated by the distance 
of the CD31 peak (endothelial cell) to the half width maximum intensity of the LEA peak (outer 
border ESL) (left and middle). WGA staining is present outside of the endothelial perimeter (right). 
C, Distribution of lectin intra- (LEA, BSI) or extra (WGA) luminal surface coverage after 4 weeks of 
active- (hyal) or inactive (ctrl) hyaluronidase treatment and after 4 weeks recovery upon osmotic-
minipump removal. Values are means ± SEM (20-40 independent measurements/glomerulus of 4 
kidneys). Difference in lectin coverage between intra- and extra luminal compartment was assessed by 
means of non-parametric Mann-Whitney U test. *P < 0.001 vs. control.
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The changes in ESL were visualized at 4 weeks of chronic infusion of active hyaluronidase, 
with inactive hyaluronidase as a control. Renal sections were stained with lectins that 
bind to b-(1,4)-linked N-acetyl-glucosamine residues (Lycopersicon esculentum, LEA), 
α-D-galactosyl and N-acetyl-α-D-galactosamine residues (Bandeiraea simplicifolia, BS-I) 
or N-acetylneuraminic acids and N-acetyl-b-D-glucosamine (Triticum vulgaris, WGA) 
(figure 2A). 
These lectins previously were shown to stain specific carbohydrate moieties in the ESL that 
correspond with intraluminal carbohydrates at the ultrastructure level [25]. To measure 
ESL thickness, the distance from the peak of the fluorescence signal of the endothelial cell 
membrane marker CD31, to the half max-intensity lectin-signal was determined (figure 
2B). In comparison to chronic infusion of inactivated hyaluronidase, both LEA (-0.14 ± 
0.06 vs. 0.73 ± 0.14 µm, p<0.001) and BS-I (0.34 ± 0.11 vs. 0.90 ± 0.08 µm, p<0.001), were 
significantly reduced upon 4 weeks of chronic hyaluronidase infusion.  After removal of 
the osmotic-minipump and closure of the catheter, recovery of the glomerular ESL was 
monitored, and both lectins (LEA and BS-I) returned to control levels (figure 2C, left 
and middle panel). In contrast, WGA predominantly bound to structures outside the 
endothelial perimeter when compared to CD31, which appeared podocyte specific (figure 
2 A-C). This extra-capillary carbohydrate staining was unaffected by hyaluronidase 
infusion (0.66 ± 0.13 vs. 0.40 ± 0.31 µm, p = ns) for 4 weeks and remained unchanged 
after 4 weeks of recovery (figure 2C right). 
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Ultra structural characterization of the glomerular endothelial surface layer
To indentify changes in glomerular endothelial surface carbohydrate structures at 
the ultrastructure level, kidneys were perfused for a short period with the cationic 
dye cupromeronic blue and further processed for transmission electron microscopy 
(TEM). In this way polysaccharides are fixated in a charge dependent way. Throughout 
the glomerulus cupromeronic blue staining was observed at various layers within the 
permeability barrier (figure 3A). As may be appreciated from the high resolution TEM 
images, compositionally different layers on the endothelial surface and the filled fenestrae 
could be observed (figure 3B and C left panel). 
The ESL staining showed dense plugs in the endothelial fenestrae and a dense layer covering 
the endothelial surface, which was coated by a more loosely attached layer (figure 3B, 
right panel and 3C, left panel). In the same capillary loop the non-fenestrated endothelial 
part displayed a denser layer of stained material (figure 3B left panel), which resembled 
previous observations of ESL in other non-fenestrated vascular beds [26,27]. The most 
striking difference between hyaluronidase-treated kidneys and their controls was the local 
absence of the dense plugs from the endothelial fenestrae (figure 3C right panel). 
Cupromeronic blue stained remaining structures covering the fenestrated endothelial 
surface, whereas the densely stained structures covering the podocytes and their foot 
processes were not affected by chronic hyaluronidase infusion. Therefore, in the mild 
dosage used, hyaluronidase infusion appeared to have predominantly removed the 
electron dense structures from the glomerular fenestrae.
Hyaluronidase infusion does not change glomerular basement membrane permeability
To exclude an effect of hyaluronidase on the glomerular basement membrane (GBM) 
barrier characteristics, retention of neutral ferritin in the GBM was measured. Total ferritin 
(2.3 ± 0.9 vs. 2.9 ± 0.9 ferritin particles/10,000nm2) in the GBM and the subepithelial 
ferritin (4.5 ± 0.9 vs. 5.3 ± 1.2 subepithelial ferritin particles/μm of GBM length) both 
remained unchanged, indicating that the hyaluronidase did not alter the composition and 
permeability characteristics of the GBM (figure 4). 
Perturbation of the glomerular endothelial surface layer results in albumin filtration
Figure 3. Transmission electron microscopic images of a cupromeronic blue stained glomerulus. 
A, Overview. Bar = 1 µm B, Capillary section with staining on top of fenestrated (right) and non-
fenestrated (left) endothelium. Bar = 200 nm B,Electron microscopic detail of glomerular filtration 
barrier (inlay). Bar = 50 nm C, Detail of glomerular filtration barrier consisting of podocytic footprocesses 
(FP), glomerular basement membrane (GBM), endothelium (EC) and endothelial surface layer (ESL) 
covering the cell membrane and filling up the fenestrae (in circle, left). Chronic hyaluronidase treatment 
for 4 weeks removed ESL from within the fenestrae (in circle, right). Bar = 100 nm
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To determine the effect of the ESL perturbation by hyaluronidase on the filtration 
barrier for albumin, kidney slices were stained for endogenous albumin. The slices were 
stained with anti-albumin conjugated to HRP and incubated with diaminobenzidine 
(DAB) to be able to visualize albumin with reflection contrast microscopy (RCM) and 
TEM simultaneously. Because the kidneys were fixed with paraformaldehyde alone, only 
bound albumin could be visualized. All unbound luminal proteins including albumin 
were washed away during staining and processing for TEM. Sections stained for bound 










Figure 4: Ferritin particles in the glomerular basement membrane. A, Electron microscopic detail of 
ferritin particles (black dots) in the glomerular basement membrane (GBM) in control and hyaluronidase 
treated mice (1 hour after a single-intravenous injection). Bar = 100 nm.  B, Ferritin particles were counted 
in the total surface area of the GBM (expressed as number of ferritin particles/10,000 nm2) or only at 
the subepithelial (podocyte) aspect (expressed as number of ferritin particles/μm of GBM length). Values 
are means ± SEM (n= 3-5 glomeruli). Difference in amount of ferritin particles was assessed by means of 
unpaired-sample t test (two-way). P = not significant
4
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Reflection of DAB was scanned and glomeruli were counted positive when DAB 
reflection was visible at the glomerular filtration barrier. A striking 90% of the glomeruli 
were positive for albumin after hyaluronidase treatment (31 glomeruli/5 kidneys) as 
observed by disperse reddish reflections outside the capillary loops (figure 5 and https://
electronmicroscopy.lumc.nl/index.html: Data, Suppl. Mat., Dane.AmJPath). In contrast, 
no albumin staining was detected in the controls (22 glomeruli/3 kidneys) and after the 
recovery period (15 glomeruli/3 kidneys). 
Using a newly developed technique to correlate the reflection found by RCM in high detail 
(at a 1.2 nm/pixel resolution), some matching glomeruli in consecutive virtual slides were 
imaged [17]. The virtual slide allows digital analysis at nanometer resolution of a whole 
glomerular cross-section in an unbiased approach, in this case for DAB stained albumin. 
The RCM images and the corresponding TEM virtual slides were correlated to determine 
the exact location of the bound endogenous albumin.
HyaluronidaseControl
Figure 5: Reflection contrast microoscpy of stained albumin in mouse glomeruli. Reflection Contrast 
Microscopy (RCM) overview of glomerular filtration barrier stained for endogenous bound albumin (arrows) 
using horse radish peroxidase (HRP) conjugated anti-mouse albumin antibody and diaminobenzidine (DAB) 
precipitation and stained with osmium tetroxide (1%) and potassium ferrocyanide (1.5%) after 4 weeks of 
inactive- (left) or active (right) hyaluronidase treatment. Upper panels = 10 μm. These online slides can be 
found at (CCDB database website URL)
84    85
Glomerular glycocalyx as barrier against albumin filtration
In the hyaluronidase-treated group albumin was mainly detected near the podocyte foot 
processes; especially in the subpodocytic spaces (figure 6a middle, both images and https://
electronmicroscopy.lumc.nl/index.html: Data, Suppl. Mat., Dane.AmJPath).  In contrast 
to the hyaluronidase-treated group, no albumin could be found past the endothelial layer 
and the glomerular basement membrane in control glomeruli (figure 3a left and https://
electronmicroscopy.lumc.nl/index.html: Data, Suppl. Mat., Dane.AmJPath). Furthermore, 
after 4 weeks of recovery, the albumin that was found after the hyaluronidase treatment 
was no longer present (figure 6a right). 
To determine whether the perturbed filtration barrier shown with TEM also resulted 
in proteinuria and albuminuria, 24-hours urine was collected. Samples were taken and 
measured before implanting the osmotic minipump (0 wks), after 4 weeks of hyaluronidase 
treatment (4 wks) and during the 4 weeks of recovery (6 and 8 wks). Although albumin 
clearly was shown to be able to pass the filtration barrier in the TEM images after 
hyaluronidase, no differences could be found in albumin/creatinin (figure 6b) or protein/
creatinin (figure 6c) levels. Since albumin also binds to podocytes and parietal epithelial 
cells in the hyaluronidase-treated group, this may suggest that uptake and degradation of 
albumin have occurred as well (figure 7). 
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Figure 6: Electron microscopic images of glomerular filtration barrier. A, Electron microscopic 
overview (upper panel) and detail (lower panel) of glomerular filtration barrier stained for endogenous 
bound albumin (arrows) using horse radish peroxidase (HRP) conjugated anti-mouse albumin antibody 
and diaminobenzidine (DAB) precipitation and stained with osmium tetroxide (1%) and  potassium 
ferrocyanide (1.5%) after 4 weeks of inactive- (left) or active (middle) hyaluronidase treatment or 
after additional 4 weeks recovery upon osmotic-minipump removal (right). Upper panels: bar = 1 μm, 
lower panels: bar = 50 nm. The online slides can be found at CCDB database website URL. B-C Urine 
measurements at start, during 4 weeks of hyaluronidase treatment and after 4 weeks of recovery in inactive- 
(white bars) and active (black bars) hyaluronidase treated mice. Measurements were done before implanting 
the osmotic minipump (0 wks), after 4 weeks of hyaluronidase treatment (4 wks) and during the 4 weeks of 
recovery (6 and 8 wks).  Values are means ± SD (n = 6 samples per group). B, protein-creatinine ratio (mg/
mg in 24-hrs urine). C, Urinary albumin-creatinin ratio (mg/mg in 24-hrs urine). Change in albumin-
creatinin ratio was assessed by means of non-parametric Mann-Whitney U test. P = not significant.
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Figure 7: Electron microscopic images of podocytes and parietal epithelium. Electron microscopic 
detail of glomerular podocyte body (upper panels) and parietal epithelial cell (middle panels) stained 
for endogenous bound albumin (arrows) using horse radish peroxidase (HRP) conjugated anti-mouse 
albumin antibody and diaminobenzidine (DAB) precipitation and stained with osmium tetroxide (1%) 
and potassium ferrocyanide (1.5%) after 4 weeks of inactive- (top) or active (middle) hyaluronidase 
treatment or after 4 weeks recovery upon osmotic-minipump removal (bottom). Bar = 200 nm. 
4
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To investigate whether albumin binding would also induce podocyte phenotype changes 
in response to injury, nephrin, synaptopodin and desmin protein expression was studied 
(figure 8). While there was a tendency towards a proliferating and migrating phenotype 
such as can be observed during podocyte effacement (low nephrin, low synaptopodin, 
high desmin) during hyaluronidase treatment, the model used was probably too mild to 
















Figure 8: Immunofluorescent staining of podocyte damage markers. Immunofluorescent localization 
of nephrin (top panels), synaptopodin (middle panels) and desmin (bottom panels) in kidneys of control 
or hyaluronidase treated mice for 4 weeks. Quantification (right row) of fluorescent intensity values are 
means of (n=50 glomeruli per n = 3 kidneys). Change in staining intensity was assessed by means of a 
Mann-Whitney U test.  *P < 0.05 vs. control.
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Discussion
Our data show that glomerular fenestrae are filled with dense negatively charged 
polysaccharide structures. Upon infusion of hyaluronidase, in a dosage that leaves the 
polysaccharide surfaces of other glomerular cells intact, but predominantly removes the 
polysaccharides in the endothelial fenestrae, albumin passage across the endothelium 
can be observed in almost all the glomeruli. Such albumin passage was not observed 
for the control animals. Treatment with low dose hyaluronidase is relatively selective 
in removing the ESL in the fenestrae while the looser glomerular surface layer appears 
structurally unaltered. Rostgaard and Qvortrup, have previously suggested the presence 
of sulfated carbohydrates in the glomerular fenestrae [28]. Our current data indicate that 
the glomerular fenestrae are relatively enriched with, easy accessible, hyaluronan. The fact 
that hyaluronan is less charged than the heparan sulfates in ESL may explain the ability 
to produce a dense mesh in the fenestrae. Interestingly, hyaluronan meshes previously 
have been shown to slow down the diffusion of macromolecules through the surface layer 
[29,30].
While hyaluronidase treatment theoretically also could affect the polysaccharide coating 
on other glomerular cells, the large scale ultra structural mapping, as well as the lectin 
staining demonstrated no structural changes between the different treatment groups. 
Chronic removal of the ESL also did not affect the glomerular ultrastructure and basement 
membrane function, while the changes in ESL and albumin filtration were completely 
reversible upon cessation of the hyaluronidase infusion. These observations lend further 
support to the notion that the glomerular ESL is dynamically regulated and that its changes 
reflect changes in endothelial function. 
Strikingly, the trans-endothelial passage of albumin was not accompanied by albuminuria 
or proteinuria. This is in contrast to our earlier experiments in apolipoprotein E (apoE) 
deficient mice on a high fat-, high cholesterol diet, which were infused with hyaluronidase 
[18]. A possible explanation for this discrepancy is that the apoE deficient mice reflect a 
double hit, where loss of ESL was superimposed on preexisting vascular and renal injury. 
This is supported by the fact that proteinuria in that model could only be provoked by co-
administration of the high fat-, high cholesterol diet. A recent study using multi-photon 
fluorescence imaging in spontaneous Munich-Wistar-Fromter (MWF) rats, also could 
relate wide spread ESL loss to the occurrence of albuminuria [31]. In the current study we 
sought to determine the role of the ESL in physiological glomerular filtration and aimed 
at a selective reversible ESL alteration where in fact only the hyaluronan mesh in the ESL 
was disrupted. This setting allows a clear conclusion on the potential of the glomerular 
ESL to prevent albumin filtration, however, the model may be less suitable to study the 
relationship between endothelial dysfunction and its association with albuminuria.
While we did not observe an increased protein excretion in the urine, we did observe 
albumin bound to podocytes and parietal epithelium. Podocytes are known to express 
4
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the megalin and cubulin transporters [32,22]. They also express scavenger receptors such 
as CXCL16 and the receptor for advanced glycation endproducts (RAGE). This raises the 
possibility that albumin was taken up by podocytes, as has also been demonstrated for 
tubular epithelium. Such uptake could initiate inflammatory signaling and contribute 
to podocyte transformation and effacement, as was postulated by Morigi et al. [34]. 
In our model, the albumin passage towards the podocyte space was associated with a 
trend towards loss of synaptopodin and increased desmin expression, but the model was 
probably too short and/or too mild to observe morphological changes in the podocytes. 
Additionally, one cannot entirely exclude that hyaluronidase treatment has caused minor 
changes of polysaccharide surface structures on the epithelial cells in such a way that 
albumin could more easily stick to these cells. However, both our cupromeronic blue and 
lectin analysis of the epithelial surface layer did not reveal any morphological changes 
after hyaluronidase treatment. At the tubular epithelium level this bound albumin was not 
found. Tubular uptake can, however, not be excluded as –in contrast to the glomeruli- we 
could not survey the whole tubular compartment.
A limitation of our study was the fact that we did not selectively disrupt the glomerular 
ESL but also affected the surface layer in other vascular endothelial beds. With respect 
to albumin filtration it is therefore of note that the enzyme treatment did not result in 
changes in blood pressure. At first sight, endothelial specific inducible knock down of the 
hyaluronidase synthesizing enzyme perhaps might be a more specific approach to test the 
functional role of the glomerular ESL. However, our experimental work in progress so far 
would indicate that, in vivo, only minor modifications of the ESL are tolerated. Complete 
removal of ESL immediately results in severe thrombotic microangiopathy as can also be 
observed with our experiments using high doses of hyaluronidase. In addition, enzymatic 
degradation of the podocytic surface layer has been shown to instantly result in podocyte 
detachment together with massive amounts of ferritin in the urinary space [35]. In this 
study, these morphological differences are not present yet. However, we do already see a 
perturbation of the glomerular filtration barrier. This suggests that the degradation of the 
endothelial surface layer presented in this study, most likely reflects an early time-point in 
the development of glomerular damage and albuminuria.
In conclusion, the glomerular endothelial surface layer functions as a selective protein 
permeability barrier, a reduction of the key component hyaluronan within this layer 
facilitates albumin passage across the endothelial layer and the GBM towards the epithelial 
compartment.
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Abstract
End-stage renal disease (ESRD) is accompanied by endothelial dysfunction. Since the 
endothelial glycocalyx (endothelial surface layer, ESL) governs interactions between 
flowing blood and the vessel wall, perturbation could influence disease progression. In 
this study we used a novel non-invasive sidestream-darkfield (SDF) imaging method, 
which measures the accessibility of red blood cells to the ESL in the microcirculation 
(perfused boundary region, PBR), to investigate whether renal function is associated 
with ESL dimensions.  PBR was measured in control participants (n=10), in patients 
with ESRD (n=23), in participants that have normal kidney function after successful 
living donor kidney transplantation (n=12) and in patients who developed interstitial 
fibrosis / tubular atrophy after kidney transplantation (n=10). In addition, the endothelial 
activation marker Angiopoietin-2 (Ang2) and shed ESL components syndecan-1 and 
soluble thrombomodulin (sTM) were measured using ELISA. Compared to healthy 
controls (1.82±0.16 µm), ESRD patients had a larger PBR (+0.23, [95%CI, 0.459 to 0.003], 
P<0.05), which signifies loss of ESL dimensions. This large PBR was accompanied by 
higher circulating levels of syndecan-1 (+57.71 [CI95%, 17.38 to 98.04] p<0.01) and sTM 
(+12.88 [95%CI, 0.29 to 25.46], p<0.001). After successful transplantation, the PBR was 
indistinguishable from healthy controls, without elevated levels of sTM or syndecan-1. 
In contrast however, patients who developed IFTA showed a large PBR (+0.36 [95%CI, 
0.09 to 0.63]; p<0.01) and higher levels of endothelial activation markers. In addition, 
a significant correlation between PBR, Ang2 and eGFR was observed (PBR vs. GFR: 
spearman’s rho 0.31 p<0.05 and PBR vs. Ang2: spearman’s rho -0.33 p<0.05).  
In this study we have shown that reduced renal function is strongly associated with low 
ESL dimensions. After successful kidney transplantation the ESL is indistinguishable from 
control.. Our new SDF-based method allows rapid and unbiased assessment of these ESL 
dimensions in clinical medicine.
5
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Introduction
Patients with end stage renal disease (ESRD) have a dysfunctional endothelium and 
increased morbidity and mortality, mainly due to their increased risk for cardiovascular 
disease [1,2]. The mechanisms responsible for activation of the endothelium in chronic 
renal failure are multifactorial and include the presence of uremic toxins (in particular 
asymmetric dimethyl arginine), low grade inflammation, and hypertension [3].  One of the 
earliest changes upon this endothelial activation has been postulated to be compositional- 
and dimensional alterations of the endothelial surface layer (ESL) [4].
The ESL is a carbohydrate gel-like layer composed of proteoglycans, glycoproteins and 
loosely bound plasma molecules [5-7]. It has been postulated to govern the interaction 
between blood and the vessel wall. Heparan sulfates, the main constituent of the ESL, have 
been shown to activate antithrombin III and to prevent leucocyte interaction with the 
endothelium [8-11]. In addition, the ESL regulates endothelial permeability and acts as 
shear stress sensor in the control of vasomotor function [12,13]. It is therefore very likely 
that alterations in, or loss of, ESL function can predispose for the development of vascular 
disease [14,15]. Under inflammatory conditions the ESL induces changes in surface 
heparan sulfate composition that facilitate the recruitment of inflammatory cells [14]. 
With sustained inflammation, the production of heparanase is induced in the glomerulus, 
which may partially degrade the ESL. Prevention of this ESL loss in diabetic heparanase 
knock-out mice also prevented the development of proteinuria and kidney injury [16]. 
Thus, ESL function and dimensions are also an important determinant of progression of 
kidney disease. 
Because the ESL is being produced and shed continuously and its dimensions are, among 
others, based on blood pressure and plasma proteins, it is very challenging to analyze 
[5-7]. Most methods that aim to detect changes in ESL are based on the measurement of 
shed ESL components like proteoglycans, hyaluronan or heparan sulfates in the plasma. 
The only direct measurements for ESL properties are currently done in animals only, using 
perfusion-staining or intra-vital techniques [13,17,18]. Until recently, ESL changes were 
measured using an invasive and time consuming method, by using the distribution of 
labeled red blood cells (RBC) and low molecular weight dextrans [19]. Recently, a non-
invasive tool for analyzing the ESL was developed using sidestream-darkfield (SDF) 
imaging. ESL dimensions were calculated as the difference in RBC column width before 
(functionally perfused capillary diameter) and after (anatomical capillary diameter) 
leukocyte passage. This technology correlates well with the invasive techniques based on 
tracer dilution to assess the volume of the ESL, which is very labor intensive and subject 
to investigator bias [20]. We use a new approach in which spatiotemporal changes in the 
ability of RBCs to penetrate the ESL can be detected [21]. This method is fully automated 
and blinded to the investigator. In contrast to previous methods, in which the ESL quantity 
was measured in volume or thickness, this method analyses ESL quality: a larger PBR, or 
increased accessibility to RBCs, reflects a disturbance of the ESL structure. 
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In the present study we utilized this method to investigate the hypothesis that renal failure 
is associated with perturbation of the endothelial ESL, i.e. larger PBR, and its relation to 
the presence of shed ESL components syndecan-1 and thrombomodulin (sTM) and the 
endothelial activation marker angiopoietin-2 (Ang2). In addition we measured the ESL in 
patients who received kidney transplantation.
 
5
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Material and methods
Study population
In a previous study, endothelial function has been shown to be estrogen-dependent and 
thus varies during the menstrual cycle [22]. Furthermore, in a currently on-going study 
we could demonstrate a small but significant difference in baseline PBR between man 
and woman (unpublished data). As the exact reason of these differences is still unclear, 
we only studied male participants in the current study to exclude gender as a possible 
confounding factor. A total of 53 male patients and 10 age-matched male controls were 
enrolled in a cross-sectional study in which PBR was measured (table 1). 31 Patients were 
included after being diagnosed with ESRD (eGFR<15 mL/min/1.73 m2), 12 with stable 
renal function after kidney transplantation (eGFR=30mL/min/1.73 m2 or higher or more, 
stable group) and  10 with interstitial fibrosis and tubular atrophy (IFTA) developed after 
kidney transplantation, (eGFR<30mL/min/1.73 m2or less and histopathologic proof, 
IFTA group). This latter group was included to investigate whether loss of function of 
the transplanted kidney would result in perturbation of the ESL. All procedures were 
approved by the Leiden University Medical Center (LUMC) institution’s Medical Ethical 
Committee and complied with the declaration of Helsinki’s guidelines. Informed consent 
was obtained from all patients.
Transplantation
All patients received kidney transplantation at the LUMC between 1984 and 2012. 
Transplantations were performed as described previously [23]. Patients were treated with 
prednisone (tapered to a dose of 10 mg by 6 weeks and a dose of 5-7.5 mg by 3 months), 
cyclosporine (area under the curve (AUC) 5400 ng.h/mL first 6 weeks then 3250 ng.h/mL) 
or tacrolimus (AUC 210 ng.h/mL first 6 weeks, then 125 ng.h/mL) and mycophenolate 
mofetil (MMF) (AUC 30-60 ng.h/mL). From the year 2000 on, these patients received 
induction treatment with basiliximab (40 mg at day 0 and 4) or daclizumab (100 mg/day 
on the day of transplantation and 10 days after transplantation). Patients were treated 
routinely with oral val-ganciclovir profylaxis for 3 months, except for a CMV negative 
donor recipient status. The clinical and research activities being reported are consistent 
with the Principles of the Declaration of Istanbul as outlined in the ‘Declaration of Istanbul 
on Organ Trafficking and Transplant Tourism.
Imaging of the sublingual microvasculature
Imaging of microcirculation: To detect the dynamic lateral RBC movement into the 
glycocalyx of the microcirculation (expressed as PBR), sidestream dark field (SDF) 
intravital microscopy (MicroVision Medical Inc., Wallingford, PA) [24] was performed 
to visualize the sublingual microvasculature. The method of calculation is based on the 
method published before and is fully automated to ensure unbiased analysis of the ESL 
[21]. The SDF camera uses green light emitting diodes (540nm) to detect the haemoglobin 
of passing RBC. The images were captured using a 5x objective with a 0.2 NA (numerical 
aperture), providing a 325- fold magnification in 720 x 576 pixels at 23 frames per second. 
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The image acquisition is automatically mediated through the Glycocheck software 
(Glycocheck BV, Maastricht, the Netherlands). With this method it is possible to detect 
increased penetration of RBCs into the glycocalyx (increased PBR) when the glycocalyx 
is perturbed or degraded.
Calculating the PBR: The software automatically identifies all available measurable micro-
vessels, in focus and without movement of the imaging unit and defines vascular segments 
every 10μm along the length of these vessels (figure 1A,B). Subsequently, a sequence of 
40 frames is recorded in time, containing on average 300 vascular segments. Then the 
observer moves the SDF imaging unit to a different location for another recording session 
of 40 frames, until a total of minimal 3,000 vascular segments are recorded. After these 
measurements, 21 line markers are placed at an interval of 0.5µm around all vascular 
segments (figure 1C,D).
From these line markers in the recorded movies, the PBR is calculated. First, the width 
of the red blood cell column is measured by determining both inflection points of the 
intensity plot profiles of all line markers (figure 1E). This results in 840 red blood cell 
column widths per vascular segment (21 line markers * 40 frames). Second, for every 
vascular segment, the measurements of all these RBC column widths are combined into a 
graph as shown in figure 1F. The number of observed RBC positions (as a percentage of the 
total) is plotted against the measured column width. From this graph the median column 
width is derived, being the 50th percentile of the curve. By linear regression analysis, the 
slope of the line between the 25th and the 75th percentile is measured. The point where 
this line intersects with the x-axis is a reliable marker (based on all 840 measurements) of 
the most outward location of the RBC, the perfused diameter (PD). 
The PBR is defined as the distance between RBC column width and PD. Because the PBR 
is present on both sides of the RBC column, it is calculated using the equation: [PD – 
median RBC column width] / 2. The calculated PBR values, classified according to their 
corresponding RBC column width between 5 – 25 µm, are averaged to provide a single 
PBR value for each participant. Finally, the PBR is schematically shown in figure 1G.
Quality checks: To ensure a reliable and reproducible measurement quality checks are 
performed during the whole analysis procedure. First, the software only selects the 
vascular segments of which at least 11 of the 21 line markers have a positive signal for 
the presence of an RBC (>50% of the vascular segment is filled with RBCs) to use for the 
subsequent analyses from the first frame of the different recordings. By selecting only the 
vascular segments that are filled for more than 50%, the influence of hematocrit on the 
PBR measurements is minimized. 
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Figure 1: Image acquisition and logarithm to calculate PBR in sublingual microvasculature.                 
A: Example of one frame made using the SDF camera. The camera detects the haemoglobin of passing 
RBCs by green light emitting diodes (540nm) and the software automatically identifies all available 
measurable micro-vessels in focus. B: Example of the same frame of the acquired image after vascular 
segments have been defined every 10μm along the length of these vessels, until at least 3000 vascular 
segments are recorded. C: Zoomed in example of one vascular segment of the RBC column. D. Sche-
matic example with the vascular segment marker and the 21 line markers on and around the vascular 
segment marker. E. Example of a plot profile of the RBC column width measured at one line marker. 
F: Graph of all RBC column widths measured at one vascular segment. From this plot the median 
RBC column width can be calculated. The perfused diameter can be determined by using linear re-
gression on the area of the curve from the 25th to the 75th percentile. Next the PBR can be calculated 
from these two parameters. G: Schematic image of cross section of a blood vessel with the RBC column 
width, perfused diameter and PBR explained.
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The second quality check is performed during the measurement of all RBC column widths 
(figure S1E). In the second quality check all measured segments are tested on minimal 
RBC width-, position of the column (centred or not) and the signal to noise ratio. In the 
third quality check the curve fit for calculating the median RBC column width and PD is 
tested (R2 of 25th to 75th percentile > 0.75)  (figure S1F). Measurement points that do not 
fulfil the criteria of these quality checks are not used for the calculation of the PBR.
Validation of the SDF method
To validate the measurements, a direct test to determine whether loss of glycocalyx dimension 
is reflected by outward radial displacement of circulating RBCs has been performed using 
intravital microscopy. For this experiment, B6.Cg-Tg(TIE2GFP)287Sato/1J mice were 
used (Jackson Laboratories, Bar Harbor, ME). In these mice endothelial cells (EC) can 
be imaged by the specific expression of GFP in ECs. These GFP-EC mice were prepared 
for intravital microscopic observation of the cremasteric microcirculation as described 
before.[25] The preparation was transferred to the stage of an intravital microscope 
(Leitz, Wetzlar, Germany), coupled to a cooled CCD video camera (C9100; Hamamatsu, 
Hamamatsu City, Japan). Microvessels were alternately observed using bright-field 
microscopy with a 435 nm band pass interference filter (blue light) in the light path for 
depiction of the RBC column and epi-illumination for examination of the GFP signal 
using the appropriate filters for fluorescein. A salt water immersion objective lens (x50, 
n.a. 1.0) was used. From these two images from the same microvessel segment (figure 
S2), the anatomic vessel width was determined using the endothelial position  by the GFP 
intensity peak while the perfused diameter was determined by the width of the RBC profile 
at half height intensity. The RBC-EC gap, or the space between endothelial cell and RBC 
column, is calculated from the difference between vessel diameter and corresponding 
perfused diameter, divided by two (as the gap is present on both sides of the RBC column). 
To determine the effect of glycocalyx degradation on the outward displacement of the 
RBC column, paired measurements in a total 16 vessels in 7 mice have been performed 
before and 30 minutes after hyaluronidase treatment (35 U, jugular vein infusion).
Laboratory and urinary assessments 
All persons enrolled in this study underwent blood sampling before the morning intake 
of immunosuppression. Creatinine, hematocrit and hemoglobin were measured. For all 
patients the eGFR was calculated from the plasma creatinine concentration using the 
Modification of Diet in Renal Disease (MDRD) formula. Simultaneously, blood was 
collected for analysis of Ang2 and sTM in serum and syndecan-1 in plasma. Ang2 (ELISA; 
R&D Systems, Minneapolis, MN, USA), sTM and syndecan-1 (ELISA; Diaclone Research, 
Besancon, France) concentrations were measured by their respective enzyme-linked 
immunosorbent assay according to the protocol supplied by the manufacturer. 
Statistical analyses 
Continuous normally distributed data are presented as mean ± SD, unless stated otherwise. 
Differences between the groups were tested by analysis of variance (ANOVA) and shown 
5
102    103
as (difference compared to control [95% confidence interval], p-value). When criteria 
for parametric testing were not met, median and interquartile range (IQR) are presented 
and tested with the Mann-Whitney test. Correlations between interval variables were 
calculated using the Spearman rank correlation coefficient. Differences were considered 
statistically significant if p<0.05. Data analysis was performed using SPSS version 20.0 
(SPSS Inc, Chicago, IL) and GraphPad Prism, version 5.0 (GraphPad Prism Software Inc, 
San Diego, CA).
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Results
Method validation in mice
To validate the PBR measurements, the gap between endothelial cells and RBC column 
(RBC-EC gap) was measured in mice before and 30 minutes after i.v. administration of 
the glycocalyx degrading enzyme hyaluronidase (supplemental methods).  RBC-EC gaps 
ranged from 0.3 – 2.6 microns (vessel diameters 5 – 35 microns). Hyaluronidase treatment 
reduced the RBC-EC gap from 1.30 to 0.52 microns (average vessel diameter 16.0 microns) 
(figure 2).  To exclude that changes in the RBC-EC gap originate from changes in the vessel 
diameter, the vessel diameter was measured before and after hyaluronidase treatment 
(figure 2). Because no changes could be observed in these paired measurements (p=0.91) 
the influence of vessel diameter can be excluded, thereby confirming that the observed 





Figure 2: Validating the method in hyaluronidase treated mice. A: Example of the epifluores-
cence- (GFP, green) and trans-illumination (RBC, black) images made for measurement of both 
the vessel width using the endothelial cell GFP signal and the perfused diameter using the RBC 
column width. B: Paired measurements of changes in EC-RBC gap before and after hyaluronidase 
treatment. (*** P<0,001) C: Paired measurements of changes in vessel diameter before and after 
hyaluronidase treatment show no differences.
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Patient Characteristics
Clinical characteristics of all patients included in this study are described in table 1. No 
differences were observed in age, blood pressure or BMI. The eGFR, was significantly lower 
in all patient groups compared to controls (p<0.05). Hemoglobin and mean corpuscular 
volume (MCV) levels were significantly lower in patients with ESRD and IFTA compared 
to controls (table 1) (P<0.05). 
 
Comparison of ESL among patient groups
Changes in ESL related to endothelial activation are hypothesized to be one of the first 
changes in the development of cardiovascular disease [4,14]. Therefore; we measured 
the distance in which the RBCs can penetrate the ESL of which the calculated PBR 
reflects the ESL barrier properties. In this study, the PBR in controls was comparable to 
the PBR measured in controls in an earlier published study with lacunar stroke patients 
[21]. Compared to healthy controls (1.82±0.16 µm), the PBR in patients with ESRD was 
significantly different (+0.23, [95%CI, 0.459 to 0.003], P<0.05). Patients who developed 
IFTA also showed a different PBR (+0.36 [95%CI, 0.09 to 0.63]; p<0.01). Interestingly, the 
PBR in stable transplanted participants was larger, but statistically indistinguishable from 
healthy controls (1.85±0.20 µm, p=1) (Figure 3). To determine the influence of dialysis on 
the PBR, we compared patients who received dialysis (n=9) with patients without dialysis 
(n=14) within the ESRD group. No difference was observed between these patient groups 
(2.02±0.21 vs. 2.07±0.29 µm respectively, p=0.62), which suggest that dialysis does not 
contribute to the observed differences in PBR (Figure 4). 
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Comparing endothelial dysfunction and shed proteoglycans 
The endothelial activation state was determined by measuring serum Ang2 levels. In 
agreement with increasing PBR, the Ang2 level was higher, although not significant, 
compared to control levels (4.21±3.23 and 2.09±1.16 ng/mL, p=0.19) in ESRD serum 
samples (figure 5a). There was no difference in Ang2 levels in the successfully transplanted 
or the IFTA group (1.68±0.85 and 3.59±2.34 ng/mL, both p=1). Next, markers of shed ESL 
compounds were measured. Serum sTM levels between control participants (7.06±1.17 
ng/mL) and ESRD patients were significantly different (+12.88 [95%CI, 0.29 to 25.46], 
p<0.001). Patients diagnosed with IFTA had even higher serum sTM levels (+34.86 
[95%CI 19.87 to 49.86], p<0.001). In participants with a stable KTx, sTM levels were 
indistinguishable from control (12.98±3.01 ng/mL, p=1) (figure 5b). In accordance, shed 
syndecan-1 levels were high compared to control (49.8 ±17.4 ng/mL) in ESRD patients 
(+57.71 [CI95%, 17.38 to 98.04] p<0.01). However, shed syndecan-1 levels were not 
significantly different from controls in both IFTA and stable KTx samples (54.8±32.7 and 






























Figure 3: Measurements of the perfused boundary region in participants with and without loss 
of renal function. PBR in healthy control participants (control, n=10), and in patients diagnosed 
with end stage renal disease (ESRD, n=23), stable kidney transplantation (stable KTx, n=12) and 
interstitial fibrosis and tubular atrophy (IFTA, n=10). Box-plot whiskers indicate 1st and 99th per-
centile. *P<0.05, **P<0.01
Figure 4: Measurements of the perfused boundary region in ESRD patients with and without 
dialysis. PBR in patient who did receive dialysis (n=9), and in patients who did not receive dialyis 
(n=14), within the ESRD group. Box-plot whiskers indicate 1st and 99th percentile.
108    109
Kidney function correlates with endothelial glycocalyx stability
Association between renal function and the endothelial surface layer
To examine any relation between renal failure, health status of the microcirculation and ESL 
composition, the following correlations were achieved (table 2). Firstly, the endothelial cell 
activation marker Ang2 inversely correlated with renal function, as assessed by the eGFR 
(Spearman’s rho=-0.40, p<0.01), suggesting a relation between endothelial dysfunction 
and renal failure. Similarly, PBR was inversely correlated with the eGFR (Spearman’s rho 
= -0.33, p<0.05) and positively correlated with serum Ang2 levels (Spearman’s rho = 0.31, 
p<0.05). A comparable inverse correlation of sTM and syndecan-1 with eGFR (Spearman’s 
rho = -0.53 and -0.67, respectively; both p<0.001) supports the indication that endothelial 



















































Figure 5:  Measurements of circulatory endothelial and ESL damage markers in participants 
with- and without loss of renal function. Markers were measured in healthy control participants 
(control, n=10), and in patients diagnosed with end stage renal disease (ESRD, n=23), stable kidney 
transplantation (stable KTx, n=12) and interstitial fibrosis and tubular atrophy (IFTA, n=10). A: 
serum Angiopoietin2 B: serum sTM and C: plasma shed syndecan-1. Box-plot whiskers indicate 1st 
and 99th percentile. *P<0.05, **P<0.01 **P<0.001
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Association between PBR and shed endothelial surface layer markers
Since both PBR and shed ESL markers associated with the observed differences in 
renal function, we tested the possible relation between the endothelial surface markers 
(table 2). Although we were able to find a positive correlation between PBR and sTM 
(Spearman’s rho=0.33, p<0.05) and between sTM and shed syndecan-1 (Spearman’s 
rho=0.45, p<0.001), no significant correlation between PBR and shed syndecan-1 was 
found (spearman’s rho=0.13 p=0.35). 
 
eGFR (ml/min/1,73 m2) PBR (µm)
PBR Spearman’s rho -0.33 -
P<0.05 -
Ang2 Spearman’s rho -0.40 0.31
P<0.01 P<0.05
sTM Spearman’s rho -0.57 0.33
P<0.001 P<0.05
Syndecan-1 Spearman’s rho -0.67 0.13
 P<0.001 P=0.35
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Discussion
We show that patients with impaired kidney function have a larger PBR, i.e. loss of 
endothelial surface layer. Interestingly, ESL dimensions in patients with a stable kidney 
transplant were indistinguishable from healthy controls, while loss of renal function in 
patients developing IFTA resulted again in perturbation of the ESL. These changes in PBR 
are reflected by the presence of circulating ESL components, sTM and syndecan-1. 
In the current study we used a new non-invasive, automated, and easy to apply approach 
to measure the ability of RBC to penetrate the ESL, quantitatively defined as the perfused 
boundary region. The automated software analysis results in an average PBR of 1.82µm in 
healthy control participants, which is lower than the previously published PBR of 3.3µm 
[26], but far more reliable because this new method uses over 3000 measurement sites and 
stringently removes artifacts and background signal. Moreover, it ensures unbiased data 
analysis.
Ang2 is released by endothelial cells upon their activation [27,28]. The paracrine release 
of Ang2 interferes with Ang1 signaling from perivascular cells towards the endothelium, 
resulting in capillary destabilization and angiogenic responses [29,30]. The correlation we 
show between Ang2, eGFR and PBR indicates that the endothelial activation during renal 
failure is associated with a loss of ESL dimensions.
TM, is an anticoagulant cell surface proteoglycan which is shed from the endothelial cell 
surface layer after inflammatory stimulation, resulting in the soluble TM we measured in 
serum [31]. Although it is also expressed in low amounts by dendritic cells and monocytes, 
it is mainly expressed by endothelial cells, thereby making it a reasonable marker for 
shedding of proteoglycans from the ESL. In this study we show a negative correlation 
between serum sTM and renal function (eGFR), which has also been shown in type 1 
diabetic patients after simultaneous pancreas–kidney transplantation [23]. Although 
shedding from the ESL most likely explains higher sTM, reduced clearance by the kidneys 
needs to be considered as well. A study in diabetic patients, however, showed that urinary 
sTM was not influenced by GFR [32]. Also the size of sTM would preclude filtration by 
the kidney. Together, these data indicate that the high levels of sTM are a direct result of 
increased TM shedding from the ESL. 
In addition to TM, syndecan-1 is also shown to be expressed at the luminal endothelial 
surface [33,34]. Its shedding from the ESL under inflammatory conditions is thought 
to contribute to plasma levels of soluble syndecan-1 [35]. In agreement, syndecan-1 
shedding has been shown previously to be associated with ischemia-reperfusion injury, 
septic shock and post cardiac arrest syndrome [33,36,37]. In addition, patients with early 
diabetic nephropathy have higher shed syndecan-1 levels compared to healthy controls 
[38]. Alternatively, reduced renal clearance of syndecan-1 could as well be involved in 
elevated plasma levels in patients with renal failure. While little is known about the exact 
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clearance mechanism of syndecan-1, its large molecular weight excludes a direct straight 
forward relationship with GFR. Although the large PBR and sTM levels coincided with 
high syndecan-1 levels in ESRD patients, transplant recipients with IFTA and reduced 
renal function still showed low levels of syndecan-1. 
Interestingly, in patients who were stable after kidney transplantation, sTM and PBR was 
not similar, but also not significantly different from the measured PBR in ESRD patients or 
the healthy controls. This position in between healthy controls and ESRD patients might 
be explained by the fact that kidney function is still not optimal compared to healthy 
controls. The higher level of sTM in IFTA patients compared to ESRD patients is absent 
for syndecan-1, which suggests that the various pathologies that underlie renal failure in 
these patients affect the shedding of ESL components differently.
All together, the plasma and serum biomarkers and PBR measurements corroborate the 
observation that loss of renal function is associated with endothelial activation and ensuing 
loss of ESL thickness.  A question is whether mucosal ESL thickness is representative for 
systemic changes. However, as with other endothelial function measurements, systemic 
factors will induce representative functional endothelial changes throughout the 
circulation. Using dextran distribution we previously validated in patients with diabetes 
that such mucosal changes in ESL thickness are indeed accompanied by changes in 
systemic ESL thickness [39]. In addition, ESL changes have also been shown to coincide in 
both the retinal and the sublingual microcirculation in patients with type 2 diabetes [40]. 
In this study we cannot completely exclude the effect of immunosuppression in the 
transplant patients on the mechanical properties of the ESL. Nonetheless, a clear change 
in PBR was observed between the kidney recipients with stable function versus the IFTA 
group, while both groups were treated with immunosuppressive medication, suggesting 
that renal function per se is a more important determinant of PBR. Another question 
is whether changes in RBC deformability may have contributed to the observed PBR 
measurements. A study by Martinez et al did not observe any alteration in erythrocyte 
deformability between control participants and patients with CKD with or without 
dialysis, which makes a contribution of RBC deformability to the observed differences in 
PBR less likely for these patients [41].
Changes in the ESL have been postulated to precede vascular (and renal) damage [4]. 
Because measuring PBR in the microcirculation is a non-invasive and fast method to assess 
changes in the ESL in patients, this is a promising new method for clinical monitoring of 
the systemic microvasculature to predict the risk for cardiovascular disease and to follow 
the vascular effect of interventions, such as kidney transplantation. 
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Abstract
Changes in endothelial glycocalyx are one of the earliest changes in development of 
cardiovascular disease. The endothelial glycocalyx is both an important biological modifier 
of interactions between flowing blood and the vessel wall, and a determinant of organ 
perfusion. We hypothesize that deeper penetration of erythrocytes into the glycocalyx 
is associated with reduced microvascular perfusion. The population-based prospective 
cohort study (the Netherlands Epidemiology of Obesity [NEO] study) includes 6,673 
middle-aged individuals (oversampling of overweight and obese individuals). Within 
this cohort, we have imaged the sublingual microvasculature of 915 participants using 
sidestream darkfield (SDF) imaging together with a recently developed automated 
acquisition and analysis approach. Presence of RBC (as a marker of microvascular 
perfusion) and perfused boundary region (PBR), a marker for endothelial glycocalyx 
barrier properties for RBC accessibility, were assessed in vessels between 5 and 25µm RBC 
column width. A wide range of variability in PBR measurements, with a mean PBR of 
2.14µm (range: 1.43- 2.86µm), was observed. Linear regression analysis showed a marked 
association between PBR and microvascular perfusion, reflected by RBC filling percentage 
(regression coefficient β: -0.034; 95% confidence interval: -0.037 to -0.031). We conclude 
that microvascular beds with a thick (“healthy”) glycocalyx (low PBR), reflects efficient 
perfusion of the microvascular bed. In contrast, a thin (“risk”) glycocalyx (high PBR) is 
associated with a less efficient and defective microvascular perfusion.
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Introduction
Cardiovascular disease is the leading cause of death in developed countries and one of the 
earliest changes in the pathogenesis of cardiovascular disease is microvascular dysfunction 
[1]. Within the inner vessel wall, a luminal endothelial glycocalyx is strategically located 
to continuously interact with the flowing blood. This endothelial glycocalyx is a thick gel-
like meshwork of proteoglycans, glycosaminoglycans and plasma proteins; it functions as 
an important biological modifier in the interaction between the blood and the vessel wall 
[2,3]. Degradation and modification of the endothelial glycocalyx is, therefore, thought 
to be one of the earliest changes occurring in the pathogenesis of vascular disease [4,5]. 
For example, the endothelial glycocalyx exerts an anti-inflammatory and anti-thrombotic 
role by covering various glycoprotein adhesion receptors for leukocytes [6] and platelets 
[7]. Also, the endothelial glycocalyx has a protective role against protein leakage, as 
shown by our group previously, when selective degradation of endothelial glycocalyx with 
hyaluronidase led to glomerular albumin leakage [4].
Another function of the endothelial glycocalyx has been proposed to be the regulation of 
microvascular perfusion. The concept that the glycocalyx contributes to the regulation of 
microvascular perfusion was originally hypothesized by the group of Duling in 1990 when 
they showed that the adenosine-induced increase in capillary tube hematocrit in hamster 
cremaster muscle vessels was diminished after enzymatic glycocalyx degradation [8]. 
Further evidence for the role of the glycocalyx in regulation of functional microvascular 
perfusion has subsequently been gathered [9-13]. Changes in glycocalyx composition 
have been demonstrated to result in a decrease of shear- dependent nitric oxide (NO) 
-mediated arteriolar vasodilation [14], to decrease functional capillary density [15] and to 
induce platelet- and leukocyte adhesion in microvessels [6,7,16]; all effects that potentially 
affect microvascular perfusion. Loss of microvascular perfusion is a principal process in 
chronic organ failure, including heart, kidney and vascular dementia. The central concept 
is that endothelial (EC) activation turns pericytes into myofibroblasts, resulting in loss 
of capillaries, tissue hypoxia and subsequent organ fibrosis. However, there is currently 
no data on the relation between health of the endothelial glycocalyx and microvascular 
perfusion regulation in man. 
Of the several methods to measure glycocalyx health in vivo, we have utilized the 
property of the endothelial glycocalyx to function as a barrier to maintain a certain 
distance between red blood cells (RBC) and the endothelial cell membrane [17-19]. To 
determine the spatio-temporal variation in radial displacement of individual RBCs into 
the endothelial glycocalyx in microvessels we used sidestream darkfield (SDF) imaging. 
SDF imaging is a non-invasive technique which visualizes hemoglobin within the RBC 
by reflected light emitting diode (LED) light from the microvasculature [20]. With this 
technique, it has been shown that the RBCs (diameter of 7 to 8μm) maintain a certain 
distance from the endothelium of capillaries (diameter of 5μm), which was postulated to 
be due to the barrier function of the glycocalyx against the RBC [19]. Using SDF imaging, 
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we imaged the longitudinal and radial distribution of RBC in sublingual microvessels to 
obtain information about the in vivo endothelial glycocalyx barrier properties in humans 
[21]. This concept has recently been tested in various patient groups with cardiovascular 
disease or risk factors, such as end-stage renal disease [17,21], stroke [18], premature 
coronary artery disease [22] and critically ill patients (septic and non-septic)[23], in 
which it was indicated that a perturbed glycocalyx allowed the erythrocytes to penetrate 
deeper towards the endothelium, resulting in an increase in the perfused boundary region 
(PBR). In addition to the lateral RBC movements, the longitudinal presence of RBCs 
(along known as vascular segments per surface area) is measured, allowing a simultaneous 
examination of the glycocalyx exclusion properties and the microvascular spatio-
temporal RBC perfusion. We hypothesized that impaired glycocalyx barrier properties 
in the sublingual microcirculation is associated with changes in microvascular perfusion 
capacity in the general population. 
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Methods
Study Design and study population
We performed a cross-sectional analysis among participants recruited for the Netherlands 
Epidemiology of Obesity (NEO) study [24] to examine the association between endothelial 
glycocalyx integrity and microvascular perfusion. The NEO study is a population-
based, prospective cohort study of 6,673 individuals aged between 45 and 65 years, with 
oversampling of overweight and obese individuals, to study pathways that lead to obesity-
related diseases for a better understanding of the mechanisms underlying development 
of disease in obesity. Detailed information about the study design and data collection has 
been described previously [24]. Men and women aged between 45 and 65 years with a self-
reported BMI of 27 kg/m2 or higher and living in the greater area of Leiden (in the west of 
the Netherlands) were eligible to participate in the NEO study. In addition, all inhabitants 
aged between 45 and 65 years from one municipality (Leiderdorp, the Netherlands) were 
invited, irrespective of their BMI, allowing for a reference BMI distribution. SDF imaging 
was performed in a random subgroup of 937 participants from the 1394 participants 
who were included from January 2012 to October 2012. The study was carried out in 
accordance with the Declaration of Helsinki. Approval was obtained from the Committee 
of Medical Ethics of Leiden University Medical Center and all participants gave written 
informed consent. 
General Measurements
Prior to the NEO study visit, participants completed a questionnaire about demography, 
lifestyle and medical history and fasted for at least 10 hours. Participants came to the 
research site in the morning to undergo several baseline measurements including 
anthropometric measurements, and blood sampling. Hemoglobin (Hb) was measured 
by the SLS hemoglobin detection method and hematocrit (Hct) by the RBC cumulative 
pulse height detection method with a Sysmex XE-2100 system (Sysmex, UK).  Extensive 
physical examination was conducted, including anthropometry and blood pressure 
measurements. Blood pressure was measured three times in a seated position on the right 
arm with a 5 minutes resting interval using a validated automatic oscillometric device 
(OMRON, Model M10-IT, Omron Health Care Inc., IL, USA). Prehypertension and 
hypertension were diagnosed according to JNC 7 criteria [25].
Imaging of microcirculation
Intravital microscopy was performed at bedside with a SDF camera (MicroVision Medical 
Inc., Wallingford, PA) to visualize the sublingual microvasculature. The SDF camera 
uses green light emitting diodes (540nm) to detect the hemoglobin of passing RBC. The 
images were captured using a 5x objective with a 0.2 NA (numerical aperture), providing 
a 325- fold magnification in 720 x 576 pixels (tissue dimension: 950 X 700µm; tissue area: 
0.665mm²) at 23 frames per second. 
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Figure 1: Glycocheck algorithm on endothelial PBR determination and microvascular perfu-
sion properties. A) Red blood cells (RBC) are detected through reflection of light emitting diodes 
by hemoglobin. Images captured by the sidestream darkfield camera are sent to the computer for 
quality checks and assessment. The black contrast is the perfused lumen of the vessels. B) In each 
recording, the software automatically places the vascular segments (green), every 10µm along the 
vascular segments (black contrast). C) After the acquisition, for the analysis, the software undergoes 
several quality check in the first frame of each recording (see text), to select vascular segments with 
sufficient quality for further analysis. Invalid vascular segments (yellow) are distinguished from the 
valid vascular segments (green). During the whole recording session of 40 frames, the percentage of 
time in which a particular valid vascular segment has RBCs present is used to calculate RBC filling 
percentage. D) Depiction of the concept of glycocalyx thickness by lateral RBC movement is shown 
here. E) For each vascular segment, the intensity profile is calculated to derive median RBC column 
width. F) Then, the distribution of RBC column width is used to calculate the perfused diameter, 
median RBC column width, and subsequently the perfused boundary region (PBR).
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The system makes up to 840 measurements of the width of the RBC column at a specific site. 
These individual width measurements are obtained after 8-fold pixel size interpolations 
of the corresponding radial intensity profiles, allowing detection of small changes in 
width between individual width measurements as small as 0.1μm, which translates in 
accuracy of estimates of boundary layer of approximately 0.05μm. The image acquisition 
is automatically mediated through the Glycocheck software (Glycocheck BV, Maastricht, 
the Netherlands) (Figure 1. for illustration of software algorithm).  It detects the dynamic 
lateral RBC movement into the glycocalyx, which is expressed as the perfused boundary 
region (PBR, in µm). Therefore, a perturbed or degraded glycocalyx would allow more 
RBCs to penetrate deeper towards the endothelial surface, which is reflected by an increase 
in PBR (figure 1d). The method of calculating the PBR has been used and validated in 
various publications [17,18,21-23]. 
In short, the software automatically identifies all available measurable micro-vessels 
(below 30µm thickness) during the acquisition by contrast between the RBC and the 
background, in focus and without movement of the imaging unit (raw data in figure 
1a). With this, it places vascular segments every 10μm along the length of these vessels. 
Subsequently, a sequence of 40 frames is recorded containing, on average, 300 major 
vascular segments (depicted as green lines in figure 1b). Next, the observer moves the 
camera to a different location to record another 40 frames, until a minimum total of 3,000 
vascular segments are placed. After acquisition, the software undergoes a series of quality 
checks to only measure vascular segments that are of good quality. First, on the first frame 
of each recording session, ten line markers are placed every 0.5µm along each side of the 
vascular segments (total of 21 line markers). Only those that have sufficient contrast on 
more than 60% of the 21 line markers of each vascular segment are considered a valid 
vascular segment (green lines in figure 1c), in contrast to the invalid vascular segment 
(yellow lines in figure 1c). Since all vascular segments are placed every 10µm, the length 
of perfused microvascular length can be expressed by multiplying 10µm and the number 
of valid vascular segments per area of tissue visualized (valid microvascular density). 
For the second quality check, during the measurement of RBC column widths for all 40 
frames of recording session, the software screens for minimal RBC width, position of RBC 
column and the signal-to-noise ratio. At this step, the software calculates the percentage 
of vascular segments with RBC present during all 40 frames of the recording session, to 
determine the RBC filling percentage. Both the valid microvascular density and the RBC 
filling percentage were used as an estimate for the microvascular perfusion. For the last 
quality check, the curve fit for calculating the median RBC column widths is tested also 
for irregularities (figure 1e). Thus, after all these quality checks, those that fulfill these 
criteria are subject to analysis for the radial distribution of RBC, as a measurement of 
glycocalyx function. 
For each vascular segment, the dynamic lateral position of RBCs (per RBC column width) 
is determined. The intensity profiles of the distribution of RBC column widths are used 
to calculate a cumulative distribution. From this distribution, the median RBC column 
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width is obtained while a linear regression analysis of the RBC column width is performed 
to derive the perfused diameter (the X-axis intercept of the extrapolated regression line) 
is calculated (figure 1f). Then, the PBR is defined as the distance between RBC column 
width and perfused diameter and is calculated using the equation, ([Perfused diameter 
– median RBC column width] / 2). Next, the calculated PBR values, classified according 
to their corresponding RBC column width between 5 – 25 µm, are averaged to provide a 
single PBR value for each participant. 
Statistical Analysis
In the NEO study there is an oversampling of persons with a BMI of 27 kg/m2 or higher. 
For the present study, to correctly represent associations in the general population,[26] 
adjustments for the oversampling of individuals with a BMI ≥ 27 kg/m2 were made. This 
was done by weighting individuals towards the BMI distribution of participants from the 
Leiderdorp municipality, whose BMI distribution was similar to the BMI distribution 
of the general Dutch population [26]. All results were based on weighted analyses. 
Consequently, results apply to a population-based study without an oversampling of 
BMI ≥ 27 kg/m2. Participants with unsuccessful measurements through SDF imaging 
(including participants with incomplete recording sessions (less than 10; n=16) and 
abnormal video images, such as consistent presence of air bubbles (n=6), all PBR outlier 
values), preventing correct analysis were excluded (n=22). In the end, 915 participants were 
included in the analysis of data. Baseline characteristics of the population were expressed 
as mean (±standard deviation [SD]), median (interquartile range), or as percentage. We 
performed linear regression analysis to investigate the associations of perfused boundary 
region with RBC filling percentage and valid microvascular density, while adjusting for 
age and sex. All statistical analyses were performed using SPSS version 20.0 (Chicago, 
IL), STATA Statistical Software (Statacorp, College Station, Texas) and GraphPad version 
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Results
General clinical characteristics
The clinical characteristics of individuals with measured SDF are shown in Table 1. All 
participants were between 45 to 65 year old. Of all participants, 42% were lean, 42% were 
overweight, and 16.0% were obese. The mean systolic blood pressure was 131mmHg (S.D.: 
16mmHg) and diastolic blood pressure was 83mmHg (S.D.: 10mmHg), with 36% with 
hypertension. 
  Table 1. General Clinical Characteristics
Total 
(n=915)
Gender (% of male/ female) 46/ 54
Age (year) 56.1± 6.0 
BMI (kg/m²) 26.4±4.2
Hb (mmol/L) 8.71 ± 1.1
Hct 0.41 ± 0.12
Hypertension (%) 33.5%
Systolic BP (mmHg) 131.0±16.2
Diastolic BP (mmHg) 83.2±9.7
 
 Hb, hemoglobin; Hct, hematocrit; BP, blood pressure. Data is presented as  
 mean ± standard deviation. 
Determination of microcirculatory properties
From the RBC column width and perfused diameter, perfused boundary region was 
calculated to derive the glycocalyx barrier function (Table 2, #1 to #3). Overall, the mean 
PBR was 2.14µm with a wide range of variability (range: 1.43- 2.86µm) (table 2). Despite 
the wide distribution of PBR in our cohort, there was a difference in PBR between men 
and women (mean: 2.09µm and 2.18µm, respectively). In addition to the glycocalyx 
barrier function by means of PBR, microvascular perfusion outcomes were calculated, 
resulting in a mean valid microvascular density of 3213μm/mm² (table 2, #5) and a mean 
RBC filling percentage of 73.2% (table 2, #6). In other words, there is 3246µm of perfused 
microvessels per mm² of tissue area which was in 73.2% positive for the presence of RBCs 
at a given time point during the 40 frames of video recording. 
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Table 2. Sidestream darkfield imaging derived variables characteristics.
# Parameter Total Men Women
1 RBC Column width 
(µm) 10.56 ± 1.12 10.74 ± 1.10 10.41 ± 1.11
2 Perfused diameter (µm) 14.84 ± 1.18 14.92 ± 1.19 14.77 ± 1.17
3 Perfused boundary 
region (µm) 2.14 ± 0.25 2.09 ± 0.24 2.18 ± 0.25
4 Total microvascular 
density (µm/mm²) 4314±882 4223±821 4391±924
5 Valid microvascular 
density (µm/mm²) 3213±691 3144±627 3272±736
6 RBC filling (%) 73.2 ± 5.0 74.0 ± 4.8 72.4 ± 5.0
Data is presented as mean ± standard deviation.
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Figure 2. Scatterplot between PBR and outcomes of microvascular perfusion. The perfused 
boundary region (PBR), a measurement for glycocalyx accessibility to red blood cells (RBC), is as-
sociated significantly with spatio-temporal aspects of microvascular perfusion variables: A) RBC 
filling percentage (percentage of time in which a particular vascular segment is perfused) B) Valid 
microvascular density. In particular, lower PBR (less accessible glycocalyx, thus a better and thicker 
glycocalyx) is associated with higher RBC filling percentage (temporal perfusion).
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Association of the glycocalyx barrier properties with microcirculatory perfusion
To test the hypothesis whether impaired glycocalyx barrier properties are associated 
with impaired microvascular perfusion, we examined the association between PBR and 
the two used estimates for microvascular perfusion (table 3 and figure 2). Of the two 
microvascular perfusion outcomes, RBC filling percentage was associated with PBR 
(regression coefficient β: -0.034; 95% CI: -0.037 to -0.031) and explained 47% of variability 
of perfused boundary region (R²: 0.475, p<0.001). The valid microvascular density was 
also associated with PBR but explained the variability of PBR to a lesser extent (R²: 
0.030), although still significant. Examples of video-clips obtained from participants with 
different PBR values and corresponding changes in microvascular perfusion are shown in 
Supplemental Video 1 and 2 (high and low PBR, respectively).
 
Table 3. Linear regression analysis show association between perfused boundary region 




coefficient β r-Square 95% CI for coefficient β
†
Lower Bound Upper Bound
RBC filling 
percentage -0.034 0.475 -0.037 -0.031
+Age, sex, BMI ‡ -0.034 0.482 -0.036 -0.031
Valid micro-vascular 
density § -0.054 0.02 -0.083 -0.025
+Age, sex, BMI ‡ -0.059 0.06 -0.087 -0.030
* Dependent variable: Perfused boundary region (PBR)
† 95% confidence interval for regression coefficient β
‡ Linear regression analysis adjusted for age, sex and BMI
§ Valid microvascular density expressed as millimeter of microvessel length per mm² of 
area of tissue (mm/mm²) for linear regression analysis due to difference in scale from 
PBR.
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Discussion
We have measured the RBC accessibility into the endothelial glycocalyx, i.e. perfused 
boundary region (PBR) together with RBC filling percentage and valid microvascular 
density in the sublingual microvasculature of over 900 participants recruited for the NEO 
study.
In this study we observed a strong association between changes in endothelial 
glycocalyx properties (PBR) and estimates of microvascular perfusion in the sublingual 
microcirculation (Figure 2 and Table 3). The strongest association existed between PBR 
and RBC filling percentage, which represents the microvascular perfusion changes over 
time. 
The mechanically stable gel-like layer on the endothelial surface limits the area in 
which RBCs and large plasma proteins are distributed (RBC exclusion properties of 
glycocalyx), which is reflected by a low PBR (figure 3a). An earlier observation of 
individual RBC in capillaries showed that compression of the RBCs by intact glycocalyx 
result in more elongated RBCs (7-8µm length and 3-4µm width), and therefore a more 
efficient and faster passage of these RBCs [19]. Also, this would lead to increased RBC 
longitudinal passage, allowing more oxygen exchange capacity. 
The relation between PBR and vascular perfusion has been studied, however, in a variety 
of different physiological stimulants, such as by exercise, nitroglycerine, adenosine or 
insulin [9,10,22]. For instance, nitroglycerine challenge in a healthy population led to an 
increase in PBR and a recruitment of reserve capacity, further arguing that in a healthy 
state of acute physiological need, the glycocalyx has the potential to become more porous 
to facilitate the increased metabolic demand [10]. With such transient stimuli, both 
PBR and perfusion increases, leading to a temporary local increase in oxygen/ nutrient 
exchange. Therefore the observed variation in PBR and its correlation with perfusion could 
theoretically be explained by this dynamic regulation. Nonetheless, we have performed 
our measurements in a strictly controlled environment (e.g. overnight fasting, resting for 
more than 15 minutes, exclusion of caffeine and smoking). Thus, the observed variation 
in PBR and clear negative correlation (figure 2b) with the microvascular perfusion would 
argue for differences in vascular health in our population.
Therefore, in an unhealthy vascular state, PBR increase (reflecting increased outward 
penetration of RBC) together with decreased RBC filling percentage and functional 
microvascular density, reflects poor perfusion (figure3b). When the glycocalyx is 
degraded for a prolonged time, protein extravasation increases with subsequent edema 
formation [4,27], and a reduction in nitric oxide bioavailability [14], all together leading 
to endothelial dysfunction and perfusion defects [10,15]. 
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Figure 3. Schematic illustration on relation between glycocalyx accessibility and microvascu-
lar perfusion. A) Healthy state: Intact glycocalyx prevents red blood cells (RBC, red dots) from 
penetrating into its domain, reflected by a low perfused boundary region (PBR), and nicely aligned 
elongated RBC. The vessels are well perfused (higher tube hematocrit of microvessel and elongated 
shape of erythrocyte) resulting in a higher percentage of vessel segments with RBC present at any 
particular time point (high RBC filling percentage).  B) Risk State: Altered composition of glycocalyx 
(lined dots) allows RBCs to penetrate deeper into the glycocalyx, closer to the anatomical border 
of lumen (endothelium), reflected by the high PBR. Due to the widening of RBC distribution width 
and volume, there is more space in between each RBC, as shown by decreased RBC filling percent-
age (less positive contrast per vascular segment per time point). Also, prolonged state of glycocalyx 
degradation leads to edematous and non-functioning vessels, leading to shorter vessel density per 
area of tissue (reduced valid microvascular density in risk PBR), depicted by the loss of bottom vessel. 
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For instance, in patients with diabetes, there is increased hyaluronidase activity [28], 
which probably decreases glycocalyx volume and functional capillary density [15,28,29]. 
The increase in distance between RBCs (reflected by low RBC filling percentage) might 
be due to both RBC changes into a wider shape [19] and more intravascular volume in 
which RBC could distribute. Ultimately, these changes lead to slow, diffuse and inefficient 
perfusion [30], as schematically depicted in figure 3. 
Variability in the width of the RBC column, and thus PBR could theoretically also decrease 
to lower values when the glycocalyx layer becomes very thin. However, it is empirically 
and consistently found in all available and known (clinical) data, that PBR progressively 
increases with the severity of disease and glycocalyx damage. The most striking increases 
in PBR are found in critically diseased patients with severe septic shock in the ICU 
(unpublished data), who are supposed to have shed off the glycocalyx [6,23]. In these 
subjects the level of PBR increase correlates directly with mortality and cardiovascular 
organ complications. It therefore appears that relatively infrequent deeper penetration of 
RBCs into the layer during degradation / damage of glycocalyx precedes the radial outside 
movement of the majority of the RBCs in the RBC column, resulting in increases in PBR 
on top of potential increases in median width of the RBC column. Moreover, in the present 
study, we performed the measurements in a large group of relative healthy participants, 
making the loss of glycocalyx in the microvasculature also a relative unlikely event.  
A question obviously is, whether glycocalyx assessment of the sublingual microcirculation 
is representative for glycocalyx dimensions in other tissues. Glycocalyx thickness and 
functional properties may indeed differ substantially from one organ to another [31]. 
However, as with other measurements of endothelial function, systemic factors will affect 
representative functional endothelial changes throughout the circulation. For example, 
using the SDF technique we and others have shown that sublingual vascular changes 
correlate with changes in the microvasculature of gastric, renal and nervous system 
organs [17,18,21,32-38]. In addition, we have shown in diabetic subjects that glycocalyx 
dimensions correlated with systemic glycocalyx volume changes [28]. Also, changes in 
the sublingual PBR in patients with coronary artery disease or stroke imply that local 
microvascular abnormalities indeed reflect changes in the systemic microvasculature 
[18,22]. 
During the past few years, there have been several methodological advances introduced in 
estimating glycocalyx dimensions. In the past, SDF glycocalyx dimensions were calculated 
as the difference in RBC column width before (functionally perfused capillary diameter) 
and after (anatomical capillary diameter) leukocyte passage [28,39]. Thereby, it measures 
the transient change in thickness due to leukocyte- induced compression of the glycocalyx. 
These previous measurements have shown reduced glycocalyx dimensions in various 
cardiovascular diseases such as diabetes [28,29], obesity [39], and hypercholesterolemia 
[40]. 
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Manually capturing leukocyte passages for a longer time period and analyzing the results 
is, however, a labor intensive process. In addition, it is subject to investigator bias. The 
current method of SDF imaging we have used, which detects the dynamic changes in 
the erythrocyte movements, acquires and analyses the recordings in an unbiased, fully 
automated fashion. 
While this technique estimates the glycocalyx thickness and microvascular perfusion 
non-invasively and automatically, it does have its limitations. First, the SDF camera only 
detects RBCs. Therefore, the perfused diameter and PBR is not the anatomical diameter 
of the vessel or the thickness of the anatomical glycocalyx, respectively. Nonetheless, by 
measuring the distribution of RBCs in a dense spatio-temporal manner, the software 
measures the location of the RBCs and can thereby statistically calculate the perfused 
diameter and PBR. In addition, we have recently validated that the measurement for PBR 
reflects actual anatomical glycocalyx damage, as shown by reduced distance between 
endothelial cell and RBC after hyaluronidase treatment using intravital microscopy [21]. 
Second, by visualizing the spatio-temporal location of the RBCs, the software estimates 
the microvascular perfusion by how often a certain vascular segment has a passing 
RBC. However, conventional outcome of perfusion variables includes RBC velocity 
or the anatomical microvascular density in a tissue [32]. Also, during the acquisition 
of approximately 2 seconds, the software cannot detect the vessel if there are no RBCs 
passing through. Therefore, it cannot visualize all vessels. 
In conclusion, SDF imaging of the mucosal microvasculature in an adjusted subgroup of 
participants recruited for the NEO study, to represent associations in a general population, 
showed a wide range of variability in RBC accessibility to the glycocalyx, which was 
negatively associated with microvascular perfusion. This means that with a thick (“healthy”) 
glycocalyx (reflected by a low PBR) there is efficient perfusion of the microvascular bed. In 
contrast, a thin (“risk”) glycocalyx (reflected by a high PBR) is associated with less efficient 
and perturbed perfusion. The strong, and until now unknown, correlations of PBR with 
microvascular perfusion in man, indicate that values of PBR might allow us to report on 
relations between these parameters during follow up of these subjects, and relate it to 
future cardiovascular risk. This is clinically very relevant as microvascular rarefaction is a 
principal process in development of chronic organ failure.
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Function and assessment of the endothelial glycocalyx 
The endothelial glycocalyx (EG) covers the endothelium throughout the whole 
vasculature. Its strategic location, between the circulating blood and the endothelium 
with its underlying tissue, points towards a potentially important functional role for the 
glycocalyx. The layer is involved in almost all functions of the endothelium;  it contributes 
to the permeability barrier, it protects against coagulation and inflammation and is involved 
in NO regulation, shear sensing and cell-cell signaling. Perturbation of this gel-like layer 
is associated with inflammation and various vasculature-related pathologies. Moreover, 
since the endothelial glycocalyx is in direct contact with pathogenic factors (e.g. elevated 
glucose, increased lipids and disturbed shear stresses) it has been proposed to be one of 
the first casualties during endothelial activation [1]. Consequently, alterations within the 
EG are proposed to be an early risk marker for vascular dysfunction. Monitoring changes 
is therefore proposed to identify early risk for cardiovascular disease. However, since it is 
difficult to keep the structure in its original in vivo state, visualization of this EG remains 
challenging.
In this thesis we studied the endothelial glycocalyx using a variety of visualization 
techniques. We showed an overview of the current techniques to visualize the endothelial 
glycocalyx in Chapter 2. By stimulating endothelial cells with prolonged shear stress, we 
aimed to mimic an in vivo situation and thereby stimulate EG production. With lectins 
and GAG-specific antibodies, we visualized compositional and dimensional changes 
within the endothelial glycocalyx after prolonged flow culture. 
In chapter 4 we used thick freshly isolated kidney slices, to diminish the influence of 
processing techniques on EG structure. After staining with lectins and endothelial 
markers, we quantified the luminal endothelial glycocalyx thickness and density. In 
addition, we used electronic microscopy in combination with cupromeronic blue, a 
compound that stabilizes and stains the EG. This enables visualization of the exact location 
of the endothelial glycocalyx in high detail and revealed the presence of dense endothelial 
glycocalyx plugs within the endothelial fenestrae. Moreover, it revealed a structurally 
heterogeneous glycocalyx on top of the endothelial layer, depending most likely both on 
endothelial phenotype and location.
In chapter 5 and 6 we used a relatively new technique to noninvasively detect changes 
in the red blood cell exclusion properties of the endothelial glycocalyx, reflected by the 
perfused boundary region (PBR). By monitoring the sublingual vasculature with SDF 
imaging in human participants, this technique can be used to evaluate microvascular 
health and perhaps even predict cardiovascular risk. With the current technique, changes 
in EG in severely diseased patients have been detected noninvasively [2-4]. 
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Structure and composition of the endothelial glycocalyx 
In vitro, the endothelial glycocalyx lacks much of its barrier function when compared to 
the in vivo situation [5,6]. Furthermore, endothelial glycocalyx dimension is reduced in 
vitro [7]. Endothelial cells in culture normally lack exposure to continuous blood flow 
and  in vivo studies revealed that a disturbed blood flow is associated with glycocalyx 
perturbation [8-10], while continuous laminar shear stress has been proposed to be 
involved in endothelial glycocalyx production [11-14]. We set out to determine the effect 
of prolonged shear stress on the endothelial surface glycocalyx in culture in Chapter 3. 
Particularly, we have focused on the role of prolonged shear stress on the compositional 
and functional changes in the luminal endothelial glycocalyx. We therefore reconstructed 
the endothelial layer to a 3-dimensional image and specifically quantified the luminal 
endothelial glycocalyx staining. 
To determine overall changes in the endothelial glycocalyx, we used the lectin wheat germ 
agglutinin (WGA). We observed an increase in WGA intensity and thickness and found 
a more homogenous distribution of the WGA staining on top of the endothelial layer. 
Previously, WGA staining on endothelial cells was decreased in a model of spontaneous 
kidney failure in aged rats [15]. Consequently, the observed increase of WGA staining 
upon prolonged exposure to flow most likely reflects an improved glycocalyx structure.
Within the endothelial glycocalyx, heparan sulfates (HS) play a crucial role in signal 
transduction from the vasculature to the endothelium and its underlying tissues. In 
particular, variation in HS disaccharide sequence and sulfation patterns determines 
binding properties for circulating proteins [16,17]. Consequently, HS are involved in many 
cellular processes such as attachment, migration, differentiation, blood coagulation, lipid 
metabolism, and inflammation [16]. Therefore we also investigated HS compositional 
changes in the glycocalyx. For this, we used the HS-antibodies 10E4 and JM403. 10E4 
has been shown to need mixed HS domains, containing both N-acetylated and N-sulfated 
disaccharide units, for binding [18]. In contrast, JM403 binding to HS depends on the 
presence of N-unsubstituted glucosamine [19]. In our study we found a marked increase 
of JM403 staining after 1 days of culture under flow. This coincided with an increase of IL-8 
gene expression. After 7 days of flow culture, the JM403 staining was hardly present. Since 
its presence is relatively rare it has been proposed that the N-unsubstituted glucosamine 
residues contribute to selective protein binding and therefore in biological and pathological 
cell processes [20]. This is supported by the finding that these N-unsubstituted HS domains 
have been demonstrated to be involved in L-selectin binding [21]. The observed decrease 
in JM403 binding therefore indicates a reduction in pro-inflammatory HS epitopes within 
the endothelial glycocalyx.
The decreased adhesion of monocytes after blocking the epitope for JM403 binding not 
only supports this hypothesis, but also suggests a direct involvement of this HS epitope 
in binding of inflammatory cells. This study shows that prolonged shear stress induces 
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an anti-inflammatory glycocalyx/HS phenotype. Moreover, it shows that endothelial 
glycocalyx composition is changed upon a shift in environment, which adds an extra layer 
of regulation to cell-cell communication by changing the binding capacity for specific 
signalling- or adhesion proteins. Consequently, modification of the endothelial glycocalyx 
is a highly interesting target to fine-tune receptor-ligand interactions on the endothelium. 
This definitely underlines the necessity for studying HS modifications in endothelial 
function.
 
The endothelial glycocalyx as a barrier in glomerular filtration 
Within the glomerulus, the glomerular filtration barrier (GFB) is the main site for 
filtration in the kidney. The GFB consists of endothelium with its glycocalyx, a glomerular 
basement membrane (GBM) and podocytes. Although it is well established that every 
single layer contributes to the glomerular filtration barrier (GFB), the exact function of the 
separate layers is still unknown. As early as 1976, Ryan and Karnovsky demonstrated that 
plasma albumin does not pass the highly fenestrated endothelial layer of the glomerular 
capillary wall [22]. The observation that the endothelial fenestrae, which are big enough to 
allow protein passage, were filled with endothelial glycocalyx indicates that this glycocalyx 
functions as a first barrier within the GFB [23,24].
In chapter 4 we demonstrated a role for the endothelial glycocalyx and more specifically 
the subcomponent hyaluronan in the glomerular filtration barrier. We show that 
glomerular fenestrae are filled with dense negatively charged polysaccharide structures. 
Upon infusion of hyaluronidase, albumin passage across the endothelium can be observed 
in almost all the glomeruli. Such albumin passage was not observed for the control 
animals. In conclusion, in this study we have shown that the glomerular EG functions as a 
selective protein permeability barrier. In support of this, endothelial glycocalyx disruption 
by displacing non-covalently bound proteins has been demonstrated to result in an acute 
increase of albuminuria [25]. Moreover, glycosaminoglycan-degrading enzymes such as 
chondroitinase and heparinase have also been shown to alter the charge selectivity of the 
glomerular filter [26,27]. In addition, in aged Munich-Wistar-Fromter rats, albuminuria 
associates with endothelial glycocalyx loss. 
Although we used a model to specifically determine the role of hyaluronan in the 
glomerular filtration barrier, it is tempting to speculate about the implications of 
glycocalyx damage in the development of renal failure. Based on the presented data we 
suggest that damage of the endothelial glycocalyx results in very early damage in the 
glomerular filtration barrier. Consequently, during diseases in which glomerular failure 
is observed, glycocalyx damage might be one of the first changes upon exposure to risk 
factors. In diabetes, for example, an increase in heparanase and hyaluronidase has been 
demonstrated, most likely as a consequence of increased levels of risk factors such as 
hyperglycemia, and hyperlipidemia [28-31]. Moreover, both hyperglycemia and diabetes 
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have been associated with a reduction in endothelial glycocalyx volume [32,33]. As shown 
in our model, the perturbation of the ESL within the glomerular filtration barrier leads 
to protein leakage and binding (/uptake) by podocytes. This could initiate inflammatory 
signalling and contribute to podocyte transformation and effacement, as was postulated 
by Morigi et al. [34], and matches early activation of podocytes observed in our model. 
When prolonging the time of damage it seems to be reasonable to expect accumulation 
of damage leading to changes in podocyte morphology. Eventually loss of podocyte 
morphology leads to a severely damaged glomerular filtration barrier.  Based on this 
model, we propose that the endothelial glycocalyx is the first casualty during prolonged 
risk factor exposure. Both the subsequent activation of endothelial cells, as the passage of 
proteins over the filtration barrier, leads to a disturbed cell-cell signalling within the GFB 
which can result in activation of endothelial cells, podocytes and mesangium (figure 1). 
However, although albumin passes the filtration barrier during this stage, we hypothesize 
that albuminuria only develops when chronic activation results in structural damage, such 
as podocyte flattening, mesangial expansion and loss of endothelial fenestrae  [35].
Early EG degradation:
Alb passes GFB  
Podocytes bind Alb and get activated
Chronic EG degradation:
Podocyte eacement
Loss of EC fenestrae
Proteinuria
Physiological situation:
EG binds proteins (Alb) 
EG allows passage of uid/small molecules
Figure 1: Schematic overview of the hypothesized mechanism of glomerular barrier failure. Dur-
ing a healthy situation the glycocalyx covers the glomerular endothelium and fills the fenestrae. Proteins, 
such as albumin, are adsorbed by the endothelial glycocalyx.  In this way they form a barrier for circulating 
plasma proteins, which are consequently unable to cross the filtration barrier. In contrast, the gel-like gly-
cocalyx allows passage of smaller molecules and fluids, thus facilitating glomerular filtration (left). During 
early endothelial glycocalyx modification and degradation, less protein can be bound and proteins can pass 
the filtration barrier. Here, proteins can bind to podocytes, parietal epithelial cells and tubular epithelial 
cells. These cells get activated as a result of binding and uptake of proteins (middle). Upon chronic EG deg-
radation, proteins continuously pass the filtration barrier. As a result, podocytes are chronically activated 
and effacement will occur. Loss of the glomerular barrier structure will eventually result in large quantities 
of proteins passing the glomerular filtration barrier which leads to glomerular and kidney failure (right).
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The observation that albuminuria in aged Munich Wistar Fromter rats associates with 
glycocalyx loss, suggests that widespread loss of the endothelial glycocalyx might link 
albuminuric kidney disease with systemic vascular dysfunction. Based on our data and 
these earlier studies, we propose that endothelial glycocalyx dysfunction is a central 
mediator in the development of both renal and cardiovascular failure [15,36].  This is 
supported by the Steno hypothesis, proposed by Deckert et al in 1989 [37]. In the Steno 
hypothesis, perturbation of the extracellular matrix, more specifically of the HS within 
this matrix, was proposed to be a key factor in the development of both renal failure 
and cardiovascular disease. We propose a revised hypothesis: Perturbation  of the 
luminal extracellular matrix, thus endothelial glycocalyx, is the central mediator for the 
development of both renal and cardiovascular failure. More detailed studies, for example 
in a model in which one could follow both the development of glycocalyx damage as 
the effects on macrovascular- and renal pathologies in time, are of utmost importance 
to study this hypothesis. When this hypothesis can be supported by future studies, the 
endothelial glycocalyx might become a crucial target for therapeutics to prevent vascular 
damage and the subsequent risk for, among others, CVD and renal disease.
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Estimating endothelial glycocalyx changes in patients using SDF imaging
As discussed in chapter 2, it is difficult to measure glycocalyx dimensions in patients. Until 
recently, shed syndecan-1 has been used, since glycocalyx shedding (e.g. in inflammatory 
conditions) is thought to contribute to plasma levels of soluble syndecan-1 [38]. However, 
the exact underlying mechanisms and dynamics of proteoglycan shedding and its link 
with various vascular pathologies are largely unknown, making it difficult to interpret this 
parameter. Moreover, the absence of shedding of one specific proteoglycan might not per 
definition mean that endothelial glycocalyx properties are  unaltered. In chapter 5 we used 
and validated a newly developed technique to estimate endothelial glycocalyx changes in 
a fast and non-invasive manner. We used this automated, and easy to apply approach to 
measure the ability of RBC to penetrate the ESL, quantitatively defined as the perfused 
boundary region (PBR) [3,39]. Overall, measuring PBR shows to be an easier and less 
invasive method than measuring shed markers like syndecan and thrombomodulin. 
However, more studies are necessary to study the selectivity and sensitivity of the PBR as 
a marker for early vascular damage.
In chapter 5 we have shown that patients with an impaired kidney function have a larger 
PBR, which reflects a loss of endothelial surface layer dimensions. Also, ESL dimensions 
in patients with a stable kidney transplant were indistinguishable from healthy controls, 
while patients developing IFTA (Interstitial Fibrosis and Tubular Atrophy) revealed a 
larger PBR, i.e. ESL loss. These changes in PBR are reflected by the presence of the shed 
ESL components sTM and syndecan-1. 
Previously, renal failure was shown to correlate with increased concentrations of shed 
hyaluronan [3], and release of the endothelium specific proteoglycan thrombomodulin 
coincides with diabetes and diabetic nephropathy [40,41]. Here, we showed that patients 
with renal failure have increased circulating levels of syndecan-1, which could be reversed 
by kidney transplantation. In addition a correlation between PBR, the glycocalyx shedding 
markers sTM and syndecan-1 and the endothelial activation marker Ang2 was observed. 
This also validates both glycocalyx measurements within this study.[42] 
Plasma and serum biomarkers and PBR measurements corroborate the observation that 
loss of renal function is associated with endothelial activation and loss of ESL thickness. 
Furthermore, we show that we are able to discriminate between a group of participants 
with and without renal failure, thereby validating the PBR measurements. Although the 
causality still needs further study, the association of glycocalyx damage, renal failure and 
endothelial activation shown in this study further supports the earlier proposed role for 
endothelial glycocalyx perturbation as a central mediator in the development of both 
renal failure and CVD. 
In Chapter 6, we set up a study to try to answer the question whether endothelial glycocalyx 
damage is predictive for the development of vasculature related pathologies. The NEO 
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study, described in this chapter, is a prospective cohort study of 6,673 individuals aged 
between 45 and 65 years, to study the mechanisms underlying the development of disease 
in obesity. Among others, we have estimated the ESL thickness in these participants as 
baseline measurement for future studies. Although in general this population is yet only at 
risk for cardiovascular disease, due to oversampling of BMI > 25, a high variation in PBR 
was observed. Nonetheless, no correlations with other known risk markers were observed, 
which might be explained by the observed high inter-individual variation. Future follow-
up of this study cohort, allowing events to occur, should address whether PBR associates 
with the development of cardiovascular disease. 
Within the baseline measurements of the NEO study we did observe an association 
between changes in endothelial glycocalyx properties (PBR) and estimates of microvascular 
perfusion in the sublingual microcirculation. The strongest association was observed 
between PBR and RBC filling percentage, which represents the microvascular perfusion 
changes over time. Although this population is only at risk for cardiovascular disease, 
the high variation in PBR and negative correlation of PBR with perfusion estimates 
might indicate the onset of the development of vascular dysfunction in a subset of these 
participants. 
In conclusion, changes in the ESL have been postulated to associate with, and maybe even 
precede, vascular and renal damage [1]. In this thesis we confirm a correlation between 
glycocalyx dimensions, perfusion, renal failure and vascular activation. Because measuring 
PBR in the microcirculation is a non-invasive and fast method to assess changes in the 
ESL in patients, this is a promising new method for clinical monitoring of the systemic 
microvasculature. Furthermore, follow-up of the NEO study cohort should address 
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Conclusion and future perspectives
The endothelial glycocalyx is a highly interactive matrix that facilitates protein-protein 
and protein-receptor interactions and thereby serves as a key modifier of endothelial 
function. Both structural dimension as well as biochemical composition determines its 
properties as a bioactive scaffold. 
The structure and modifications of carbohydrates are highly complex and exceed the 
complexity of proteins and genes. Studying glycocalyx composition has proven very 
challenging due to the structural fragility and the complex sugar biochemistry involved. 
However, modern imaging technology, as discussed in this thesis, opens up opportunities 
to take the glycocalyx into account when studying vascular and renal physiology. While 
it is still technically impossible to unequivocally chemically characterize HS and HA 
variability, most of our knowledge on disaccharide modification - function relationships 
needs to be derived from experiments where enzymes that edit the chemical composition 
of the glycocalyx are conditionally knocked out. The development of new methods to study 
the exact structure and composition of this luminal endothelial glycocalyx is therefore of 
key importance to obtain more insight in the endothelial glycocalyx function.
Together with earlier published data [43], our data in chapter 4 and 5 points towards 
a central role for endothelial glycocalyx perturbations in the development of both 
cardiovascular disease and renal failure. Consequently, the role of endothelial glycocalyx 
damage in development of vascular related pathologies needs to be further studied. The 
development of the SDF camera might enable us to study glycocalyx perturbations in 
large cohorts. For now, structural dimensions of the glycocalyx have been measured using 
SDF imaging in severely diseased patients [3,44,45]. However, to be able to detect early 
glycocalyx damage and thus predict the development of cardiovascular disease, further 
development and optimization of this technique is required. 
Altogether, development of further insight in structure-function relationships of the 
glycocalyx will create new perspectives in our understanding of physiology and provide 
opportunities to innovate medicine. Development of technological innovations that 
enable the further interrogation and the modulation of glycocalyx function will prove to 
be a critical success factor. 
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In dit proefschrift staat de endotheliale glycocalyx centraal. Hoofdstuk 1 is een algemene 
introductie, waarin de compositie en functie van de glycocalyx algemeen in zowel alle 
vaten, als meer specifiek in de glomerulus van de nier beschreven wordt. De glycocalyx 
is een vaat-beschermende gel-achtige laag tussen het stromende bloed en de vaatwand. 
Deze laag bevat eiwitten met vele suikerketens, vandaar de naam glycocalyx, (glykys = 
zoet, kalyx = schil). Deze suikerketens kunnen eiwitten binden en deze zo efficiënter 
bij de specifieke receptor op de doelcel brengen, of juist ver van deze receptor houden. 
Wanneer de endotheelcel geactiveerd raakt, bijvoorbeeld tijdens ontstekingen, veranderen 
deze bindingsplaatsen zo dat andere eiwitten uit het bloed (bijvoorbeeld eiwitten die 
ontsteking bevorderen) hier kunnen binden en hun effect kunnen uitoefenen op de cel. 
Aangezien de endotheelcel continu in direct contact staat met het bloed, is de glycocalyx 
betrokken bij bijna alle functies van het endotheel. In eerdere studies is aangetoond dat de 
glycocalyx beschermt tegen ontsteking, stolling en de ontwikkeling van eiwitlekkage. Een 
beschadigde glycocalyx kan daarom leiden tot hart en vaatziekten, maar ook tot (indirecte) 
schade in andere organen, zoals in de nier. In dit proefschrift hebben we de compositie 
van de endotheliale glycocalyx in endotheelcellen bestudeerd. Vervolgens hebben we meer 
specifiek de rol van de glycocalyx in de filterfunctie van de nier onderzocht. Uiteindelijk 
hebben we gekeken naar glycocalyx schade bij patiënten met nierfalen.
In Hoofdstuk 2 hebben we de huidige technieken voor het detecteren van de glycocalyx 
beschreven. Dit zijn vooral visualisatietechnieken zoals elektronenmicroscopie en 
fluorescentiemicroscopie. In dit hoofdstuk beschrijven we ook SDF visualisatie van 
de microcirculatie en daaropvolgende schatting van veranderingen in de dikte van 
de glycocalyx. Dit gebeurt door het meten van de zijwaartse verplaatsing van rode 
bloedcellen, die gevisualiseerd worden doordat hemoglobine (in rode bloedcellen) het 
licht van de SDF camera absorberen. Wanneer de glycocalyx beschadigd is, kunnen rode 
bloedcellen dichter bij het endotheel komen en zich dus verder zijwaarts verplaatsen. Het 
grote voordeel van deze techniek is dat het mogelijk is om de glycocalyx non-invasief te 
meten zonder de laag uit de in vivo omgeving te halen. Dit maakt het een veelbelovende 
techniek voor studies naar de mogelijkheid tot het gebruiken van glycocalyx schade als 
vroege marker voor vasculaire schade in patiënten. Voor meer specifieke studies naar 
de compositie en functie van de glycocalyx zijn microscopie en specifieke kleuringen 
echter nog steeds de best mogelijke techniek. De glycocalyx is echter een instabiele en 
dynamische laag, waardoor het lastig is deze laag intact te houden buiten het lichaam. 
Ondanks deze uitdagingen hebben de specifieke kleuringen geleid tot inzichten in de 
compositie en functie van de verschillende componenten in de glycocalyx.
In hoofdstuk 3 hebben we deze compositie en functie van de glycocalyx in vitro bestudeerd. 
In eerdere studies is gebleken dat de glycocalyx dunner en minder functioneel is in cellen 
die in vitro (buiten het lichaam) gekweekt zijn. Deze cellen missen vele factoren vergeleken 
met de in vivo (in het lichaam) situatie, waarvan stromend bloed een van de meest cruciale 
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is. Eerder was al beschreven dat endotheel cellen die gekweekt worden in een omgeving 
waarbij medium over de cellen stroomt meer lijken op de cellen in bloedvaten. In dit 
hoofdstuk laten wij zien dat de glycocalyx in de cellen waarover medium stroomt dikker 
en dichter is dan in cellen waarbij dit niet is gebeurd. Verder laten we zien dat binnen 
de glycocalyx specifieke eiwitbindingsplaatsen in de heparan sulfaten veranderen. Deze 
veranderingen zorgen ervoor dat de endotheellaag minder inflammatoire cellen bindt 
na een inflammatoire stimulus. In dit hoofdstuk laten we dus zien dat stromend bloed 
ervoor zorgt dat zowel de cellen als de glycocalyx meer gezonde kenmerken krijgen. Als 
gevolg zou je kunnen speculeren dat vaten met een verstoorde bloedflow (bijvoorbeeld op 
plaatsen waar atherosclerose plaats vindt) niet alleen een ongezonde endotheelcel maar 
ook een beschadigde glycocalyx hebben. 
In hoofdstuk 4 hebben we de rol van de glycocalyx in de filterfunctie van de nier bestudeerd. 
Meer specifiek hebben we gekeken naar de rol van een van de suikercomponenten 
van de glycocalyx: hyaluronan. Wij denken dat de glycocalyx een barrière vormt voor 
grote eiwitten, terwijl het water en kleinere moleculen doorlaat. Op deze manier zorgt 
de glycocalyx ervoor dat belangrijke eiwitten en cellen in het bloed behouden blijven. 
Hyaluronan heeft een belangrijke functie in deze barrière. Het is namelijk al langer bekend 
dat een gel-achtige laag van hyaluronan makkelijker kleine dan grote stoffen doorlaat. Om 
dit te onderzoeken hebben we muizen een maand lang een constant infuus van kleine 
hoeveelheden hyaluronidase, een enzym wat hyaluronan afbreekt, gegeven. Vervolgens 
hebben we gekeken naar het effect op de glycocalyx en het effect op de filtratie barrière 
in de nier. Ten eerste zagen we dat vooral de glycocalyx in de fenestrae (gaten in de 
endotheelcellen waardoor vloeistoffen de filtratie barrière kunnen passeren) verdwenen 
was na behandeling met hyaluronidase. Hoewel we geen verhoging van albumine terug 
konden vinden in de urine, zagen we wel degelijk dat albumine de filtratie barrière 
gepasseerd was. Dit geeft aan dat de verstoring van de glycocalyx door het afbreken van 
hyaluronan leidt tot een verslechtering van de filtratie barrière. Ook zagen we dat albumine 
voorbij de filtratie barrière gebonden was aan podocyten, wat samenging met een lichte 
verhoging van schademarkers aan deze podocyten. Dit wekt de suggestie dat podocyten 
beschadigd raken, mogelijk doordat relatief grote hoeveelheden albumine gebonden 
worden. Deze data impliceert dat beschadiging van glycocalyx het begin in de ontwikkelin 
van uiteindelijke nierschade kan zijn. Dit kan bijvoorbeeld zo zijn bij de ontwikkeling van 
nierfalen als gevolg van suikerziekte, een ziekte waarin enkele studies aangetoond hebben 
dat de glycocalyx beschadigd raakt. 
Vervolgens hebben we naar glycocalyx-schade als marker voor (beginnende) vaatschade 
gekeken. In hoofdstuk 5 hebben we de glycocalyx-dikte gemeten met de eerder 
beschreven SDF camera in patiënten voor en na een niertransplantatie. Hier zagen we 
een vermindering van de dikte van de glycocalyx in patiënten met nierfalen vergeleken 
met gezonde controles. Na succesvolle niertransplantatie was de glycocalyx weer 
hersteld naar waardes zoals gemeten in gezonde controles. Na een minder succesvolle 
transplantatie was dit herstel niet te zien. De met de SDF gemeten glycocalyx-diktes 
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correleerden met circulerende glycocalyx afbraak-markers (syndecan, sTM), endotheel-
activatiemarkers (Ang-2) en markers voor nierschade (GFR). Dit geeft duidelijk aan dat 
samen met endotheel activatie, de endotheliale glycocalyx ook beschadigd is in patiënten 
met nierfalen. Aangezien verwacht wordt dat schade aan de glycocalyx vooraf gaat aan 
vasculair en mogelijk ook renaal falen, is het meten van de endotheliale glycocalyx met 
een SDF camera een veelbelovende manier om op een non-invasieve manier de vasculaire 
(glycocalyx) status te monitoren. Hoewel meer studies nodig zijn, zou het een manier 
kunnen zijn om het risico op cardiovasculair- en mogelijk zelfs nierfalen te voorspellen.
Een studie met als uiteindelijke doel om uit te zoeken of dit inderdaad mogelijk is, is 
beschreven in hoofdstuk 6. De hier beschreven NEO studie, bestaat uit personen met 
een gemiddeld tot hoge BMI. Op basis hiervan hebben deze personen een hoger risico 
op cardiovasculair falen. Hoofdstuk 6 beschrijft de studie en de eerste basismetingen van 
de glycocalyx met SDF. Uiteindelijk worden deze patiënten vervolgd, zodat mogelijke 
complicaties op kunnen treden en gekeken kan worden naar de voorspellende waarde 
van de SDF metingen. Hoewel deze data nog niet beschikbaar is, vonden we wel een 
interessante correlatie tussen glycocalyx dikte en de perfusie van de gemeten vaten. 
Ondanks dat we nog geen vervolgmetingen hebben kunnen doen, zou de combinatie van 
dunnere glycocalyx en verslechterde perfusie al een hint kunnen zijn richting aangetaste 
microvaten. Toekomstige data moet uitwijzen of dit inderdaad zo is en of vervolgens 
de schattingen van de glycocalyx dikte aan de hand van metingen met de SDF camera 
gebruikt kunnen worden om cardiovasculair risico te voorspellen en zo preventief in te 
kunnen grijpen bij ogenschijnlijk gezonde personen.
Hoofdstuk 7 is een samenvatting en uitgebreide interpretatie van de data die in dit 
proefschrift beschreven is.  
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